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Infertility is traditionally defined as failure to achieve pregnancy after 12 or more 
months of regular unprotected intercourse; an estimated 10-15% of women experience 
infertility at some point in their reproductive life. The majority of infertility research has 
been focused on couples actively seeking treatment in specialty clinics, overlooking 
individuals who are infertile but not seeking medical specialty treatment. This 
dissertation uses data from the Fertility Experiences to examine the complexities of 
infertility research, treatment and interventions, and outcomes. Aim 1 compares 
approaches to collecting information about pregnancy attempt duration and identifies 
predictors of misestimating time at risk for pregnancy when assessing duration using a 
single question compared to discrete date event histories. Aim 2 provides information on 
the use of interventions to enhance fertility over the course of the reproductive life. Aim 3 
examines the association between infertility treatment (ovulation stimulation, intrauterine 
insemination (IUI), and in-vitro fertilization (IVF)) used during the cycle of conception 
and preterm birth (<37 weeks completed gestation) using subfertile women who 
conceived spontaneously, without medical treatment, as controls.  
Aim one found that two-thirds of women substantially misestimated their 
biological time at risk for pregnancy when asked a single question. Detailed attempt 
histories, capturing specific dates, can provide a more nuanced assessment of biological 
  
 
time at risk of pregnancy, duration of intentional pregnancy attempt, and specifically the 
number of cycles where fertility focused intercourse is being used to ensure appropriately 
timed intercourse.  Aim two found that women commonly use both medical and 
nonmedical interventions while trying to conceive. Primary care clinicians and fertility 
specialists should assume that nearly all their patients are using some type of nonmedical 
intervention and should take a full history that includes assessment of behavioral changes 
and complementary and alternative medicine. Aim three found that all fertility treatments 
(ovulation drugs, IUI, and IVF) were associated with a higher incidence of preterm birth, 
predominantly related to multiple gestation births. The findings support the use of 
treatment protocols that maximize singleton gestation. In addition, the findings highlight 
the increased risk of preterm birth in pregnancies conceived using any medical fertility 
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1.1 Overview of Subfertility 
 
Subfertility, also called infertility, is traditionally defined as failure to achieve 
pregnancy after 12 or more months of regular unprotected intercourse. About 15% of 
women in the United States who are currently attempting to conceive are experiencing 
difficulty becoming pregnant.1-3 About half of these women seek medical treatment, with 
significant disparities among socioeconomic and ethnic groups.1,4,5 Subfertile couples and 
their clinicians choose among a variety of treatment options.6,7  
 
1.2 Etiology and Management of Infertility in the United States 
There are varying degrees of subfertility and a variety of potential underlying 
causes: abnormalities in oocyte production; abnormalities in sperm production; 
abnormalities in reproductive tract transport of the sperm, oocyte, and/or embryo; 
abnormalities in the implantation process; or other conditions that affect one or multiple 
components of the reproductive process.8 Diagnostic tests, monitoring biosymptoms, and 
tracking menstrual cycle patterns can help to determine the underlying etiology of the 
unsuccessful pregnancy attempts.9 However, providers are frequently unable to identify 
the precise cause of a couple’s subfertility and in 15-30% of cases assign more 
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ambiguous diagnosis of unexplained infertility.10  In the United States, about half of 
couples who have difficulty conceiving seek medical treatment to address their 
subfertility.11 Common medical approaches to overcoming subfertility include the use of 
ovulation stimulation (OS), intrauterine insemination (IUI), and in vitro fertilization 
(IVF). 
Women with ovulatory dysfunction are commonly treated with fertility drugs that 
stimulate ovulation.12 Clomiphene citrate (CC), brand names Clomid® and Serophene®, 
is the most commonly used oral medication for ovulation indication. The general 
principle behind CC is that it acts on the pituitary gland to increase secretion of FSH, 
which in turn stimulates the maturation of ovarian follicles. In successful CC treatment, 
the pituitary gland becomes hypersensitive to gonadotropin-releasing hormone (GnRh), 
which causes a luteinizing hormone (LH) surge, which signals the release of an egg from 
the mature follicle during ovulation.  
Intrauterine insemination (IUI) is most commonly used when male factor is a 
contributor to a couple’s infertility. Couples in which the male has low sperm count or 
impaired sperm motility may benefit from this type of fertility treatment as it allows for 
semen to bypass the cervix.13 IUI consists of collecting semen, then washing the ejaculate 
to remove prostaglandins and other factors. The sperm is then concentrated in a small 
volume of culture media that enhances capacitation and the acrosome reaction.8 The 
mixture is then injected directly into the upper uterine cavity using a small catheter 
threaded through the upper cervix.13 This procedure is timed just prior to ovulation. IUI 
success depends on the cause and severity of the couple’s infertility. IUI is most 
beneficial for couples if the man has motility issues or the woman has cervical factor 
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infertility. IUI does not help couples in which the women suffer from tubal factor 
infertility, or severe endometriosis, or men have very low sperm count.13 
IVF is used to increase the chances of conceiving in multiple underlying causes of 
infertility. It consists of various steps including ovarian stimulation, egg retrieval, 
fertilization, embryo culture, and embryo transfer.14 With IVF, both the oocyte and the 
sperm are handled outside of the body. Semen is collected from the male partner and 
either placed in the petri dish with the egg overnight or a single sperm is injected directly 
into each mature egg, a procedure known as intracytoplasmic sperm injection (ICSI). 
ICSI is used in about 60% of assisted reproductive technology (ART) cycles in the 
United States.14 
In the past 3 decades, the focus of fertility research and treatment has increasingly 
shifted from less invasive medical treatments (including OS and IUI) to the more 
invasive IVF.  IVF was originally developed to overcome absolute subfertility due to 
blockage or absence of the fallopian tubes and later expanded to treat severe male 
subfertility with the addition of intracytoplasmic sperm injection (ICSI) (i.e., specific 
indications for IVF), but is now frequently used for couples with diminished fertility due 
to any cause as well as those with infertility of unknown cause.15,16 While providers 
advocate that IVF should become a primary management strategy for couples without 
specific indications because of its high probability of per cycle success, there are 
substantial concerns about expanding use of IVF, including high cost and impact on 
neonatal outcomes.15,16 The proportion of live births conceived through IVF average 
1.4% in the United States but vary by region (range: 0.2% in Puerto Rico to 4.3% in 
Massachusetts)17; however, across the nation IVF births contribute to a considerable 
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proportion of the preterm births (PTB, <37 weeks completed gestation) and low 
birthweight (LBW, <2,500 grams) infants born each year. No formal surveillance exists 
for the less invasive fertility treatments, but exposure to these fertility treatments (OS and 
IUI) may also be associated with adverse perinatal outcomes.18-20 It is estimated that OS 
accounts for up to 6% of the births in the United States, and about 1% of births results 
from IUI.7,18 Therefore, monitoring birth outcomes and assessing risks associated with 
each of these medical exposures are critical public health concerns. Additional questions 
remain as to whether PTB and LBW are related to the treatments or to the underlying 
causes or severity of the subfertility.21,22 Few studies exist that assess the independent 
risks of subfertility’s association with PTB and LBW.23  
In addition to medical treatments, couples that are experiencing unwanted 
childlessness might use nonmedical or behavioral interventions. Some of these 
interventions have data supporting their effectiveness, while others need more research.24-
31 Data exist to support the use of fertility-focused intercourse to increase per-cycle 
pregnancy rates in couples without evidence of infertility.32,33 Fertility-focused 
intercourse approaches include tracking basal body temperatures (BBT), using luteinizing 
hormone (LH) test kits, monitoring cervical mucus (CM), and counting cycle days using 
a simple calendar method to predict fertile days. Other nonmedical interventions include 
losing or gaining weight to achieve a “normal” or healthy body mass index (BMI) and to 
improve overall health and reproductive capacity.34 Although different from weight 
management interventions, another behavioral change that is sometimes reported is the 
use of fertility diets. Fertility diets typically recommend changing micronutrient profiles 
to enhance fertility.35 Couples having difficulty conceiving may turn to complementary 
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and alternative medicines (CAM). Although there are many CAM approaches that have 
been explored, some of the more commonly reported fertility-related interventions 
include the use of vitamins, herbs, and/or acupuncture.36,37 
 
1.3 Development of the Fertility Experiences Study 
Most of the data available for reproductive outcomes of fertility treatments are 
biased. Data that are collected from patients enrolled from specialty fertility clinics are 
likely not representative of all women and couples seeking to become pregnant, selection 
bias, because many couples seek treatment from other types of providers.4,38,39 Similarly, 
many studies focus on outcomes for treatment with assisted reproductive technologies 
(ART), which complete early stages of human reproduction in vitro, but fewer studies 
address outcomes for non-ART fertility treatments, and fewer still for spontaneous 
conceptions among subfertile couples, information bias.40 Inferences about effects 
associated with specific treatments require appropriate comparisons to other subfertile 
couples receiving other treatments, or no treatment.38,41,42 
To address these gaps, we conducted an observational, retrospective cohort study 
with parallel clinic-based and population-based cohorts of women residing in the state of 
Utah, who had a history of primary infertility (i.e., trying to conceive for at least one 
year, with no prior pregnancies) as of an index date between 2004 and 2008. The clinic-
based cohort was recruited from the two major specialty fertility clinics in Utah during 
the time of the study, while the population-based cohort of women was recruited based 






1.3.1.1 Design and target populations 
 
 The Fertility Experiences Study (FES) consists of two retrospective cohorts. For 
the clinic-based cohort, we sought to enroll women seen for an initial visit for primary 
subfertility at one of the two participating fertility specialty clinics during specific time 
frames within 2004-2008: the Utah Center for Reproductive Medicine (UCRM), affiliated 
with the University of Utah, or the Reproductive Care Center (RCC), a private practice. 
Both practices are located in the Salt Lake City metropolitan area and serve a referral 
base that includes the entire state of Utah. For the population-based cohort, we sought 
women from the entire state of Utah who had also experienced primary subfertility in 
parallel time frames. 
 
1.3.1.2 Preliminary eligibility 
All potential participants had to meet initial eligibility criteria prior to recruitment, 
as shown in Table 1.1. At the UCRM, 2 index years were chosen: 2004 and 2008. For 
RCC, the range of 2000-2009, inclusive, was chosen. Clinic records were used to 
determine preliminary eligibility for these women. We attempted to contact all women 
meeting preliminary eligibility criteria for the UCRM 2004 clinic sample and the RCC 
sample. We attempted to contact a random sample of women from the UCRM 2008 
cohort. 
For the population cohort, preliminary eligibility was determined from records 
within the Utah Population Database (UPDB); marriage and divorce records were linked 
to birth certificates and fetal death certificates, with contact information coming from 
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various public records linked by the UPDB, including drivers’ license renewals. 
Preliminary criteria were designed to identify married women who remained in 
partnership, continued as Utah residents, and had no identified birth or fetal death within 
2-5 years of the marriage date. The population cohort had two period subcohorts: one 
with an index date of December 31, 2004, and the other with an index date of December 
31, 2008. Within each of these subcohorts, UPDB generated a random sample of women 
meeting preliminary eligibility criteria, to be contacted by the independent designated 
intermediary agency for recruiting participants from the UPDB, called the Resource for 
Genetic and Epidemiologic research. 
 
1.3.1.3 Recruitment and screening 
All potential participants were sent a letter by mail, explaining the study and 
inviting them to respond regarding their interest in the study. Potential participants in the 
clinic cohort received a letter from their clinic, signed by the director of the clinic and the 
principal investigator for the study (JBS). This letter invited them to respond to study 
personnel by phone or email or go directly to a web-based response page. Response 
options included immediately completing the screening questionnaire (for phone or 
email), requesting further information, or requesting not to be contacted further about the 
study. Study staff tracked bad mailing addresses and attempted to make follow up 
telephone calls for women from UCRM. Due to clinic staffing limitations no address 
tracking or telephone calls were made for women from RCC. 
Potential participants in the population cohort received a mailed letter from RGE 
explaining the study and inviting them to respond regarding their interest in the study. 
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They were invited to respond to RGE by mail, telephone, or online web form. Response 
options included requesting their contact information to be given to study personnel, or 
requesting not to be contacted further about the study. For women interested in 
participating, their contact information was given to study staff, who subsequently invited 
them to be screened for final eligibility.  RGE staff also tracked bad mailing addresses 
and attempted to contact by telephone those women who did not respond to the initial 
letter from RGE. 
 
1.3.1.4 Final eligibility, enrollment, and consent 
All potential participants completed the screening questionnaire by telephone or a 
web form, using Opinio software. The screening questionnaire took less than 5 minutes to 
complete. Final eligibility criteria were the same for both the clinic and population 
cohorts and are shown in Table 1.2. These criteria were designed to identify women with 
primary subfertility at their index date for the study, who had at least 3 consecutive years 
of residence in Utah after the index date. 
Women who met final eligibility criteria were immediately invited to participate 
in the study. Enrollment in the study consisted of completing the initial portion of the 
study questionnaire, described further below. In the first screens of the online 
questionnaire, the study procedures were explained, and women were informed that 
completing the questionnaire constituted their informed consent. The study was reviewed 
and approved by the University of Utah Institutional Review Board for research 




1.3.1.5 Duplicate participants between cohorts 
Duplicates participants between cohorts (including the two clinical subcohorts) 
were possible. During screening some respondents notified us that they had previously 
participated in the study; in these cases, we retained their first response only. After 
responses from all cohorts were received, we identified remaining duplicate responses by 
name, birthdate, or email address. In this way, we identified five additional duplicates: 
three that had responded to both the population invitation and the UCRM invitation and 
two that had responded to both the population invitation and the RCC invitation. For 
these five women, we utilized the data from the responses given to the clinic invitation. 
Although some women had received care at both UCRM and RCC, they responded to 
only one clinic invitation: we identified no duplicates between the clinic cohorts using 
name, birthdate, or email address. 
 
1.3.1.6 Design of the questionnaire 
We initially conducted a literature review to identify questionnaires that possibly 
included domains of interest for our research (Table 1.3). 43-53 We also contacted authors 
to obtain copies of their instruments, where possible. We used items verbatim from some 
questionnaires.44,45 Based on this review and consultation with experts in the field, we 
constructed a questionnaire with the domains of interest for our research, called here the 






1.3.1.7 Pilot testing 
We pilot tested the FEQ in four sequential phases by self-administration (written), 
by face-to-face interview, by telephone interview, and by mixed-mode of administration 
(written, followed by interview).  Revisions of wording of some items and responses 
were undertaken, informed by each phase.  A total of 17 current patients of UCRM were 
included in the pilot testing. Based on the pilot work, we found that mixed-mode 
administration was most efficient to yield complete and internally consistent information 
on attempts to conceive (as described further below). We also found that we had more 
complete and internally consistent information regarding pregnancy outcomes, fertility 
treatments, and self-help measures when these were likewise assessed first in writing, 
with a follow-up telephone interview.  
 
 
1.3.1.8 Data Collection 
 
Participation in this study consisted of completing a mixed-mode, two-part 
questionnaire, the Fertility Experiences Questionnaire (FEQ). The first phase of the FEQ 
was administered via the internet, using Opinio software, taking 25-45 minutes to 
complete. In a few cases, women completed a paper questionnaire and returned it by 
mail. The second phase was an in-depth phone interview conducted by trained study 
staff, requiring between 20 and 45 minutes to complete. 
 In both phases of the FEQ, quantitative and qualitative data were collected, 
including reproductive history, fertility treatment history, feelings surrounding infertility 
and treatments, treatment choices, and pregnancy outcomes that directly resulted from 
each attempt. After study data collection was complete, we mailed a letter to all study 
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participants informing them that we planned to link their study data to Utah vital records 
for birth certificates and fetal death certificates. Only seven individuals opted out of the 
linkage section of the study. The UPDB linked enrolled participants to vital records and 
data from the Utah Birth Defects Network. Women who completed both the online and 
telephone portions of the FES were sent a $10 gift card for a local grocery store, with a 
handwritten thank you note from the study staff. 
 
1.4 Validation of FES Questionnaires 
Our goal, with the creation of the FEQ, was to generate an instrument that can be 
used retrospectively to ascertain fertility treatments chosen by women, reasons for 
choosing or declining different treatments, factors that may have influenced choices of 
treatments, timing of treatments, and a detailed history of attempts to conceive (by which 
we mean time at risk of pregnancy, as defined further below). We conducted a validation 
comparing components of the questionnaire with data from medical records in a clinical 
sample.  
 
1.4.1 Attempts to conceive or time at risk of pregnancy 
The “pregnancies and attempts to conceive” component of the FEQ captures 
information about all time in a woman’s life when she was at risk of pregnancy, whether 
or not she was “trying” to conceive, and whether or not the “attempt” ended in 
pregnancy.  Each time period at risk of pregnancy is called an “attempt” to conceive in 
the FEQ. The written questionnaire contains a definition as well as an illustrative 
example for “attempts to conceive” to enhance respondents’ understanding of the concept 
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of “attempts to conceive.” Several initial questions are asked in the written questionnaire, 
with a follow-up telephone interview for further verification and clarification. The goal is 
to capture as accurately as possible the time a woman was actually at risk of pregnancy.  
Unlike other time to pregnancy (TTP) questions that ask a woman to report a general 
number of months it took to become pregnant, the “attempts to conceive” section 
specifically excludes time that a woman was not at risk for pregnancy (for example, due 
to spousal separation, or desire not to have a baby in a certain month), even though she 
may have intended to achieve a pregnancy.54 It also explicitly includes time that a woman 
was at risk of pregnancy without intending pregnancy.55 This issue is explored in detail in 
Aim 1 of this dissertation. 
 
1.4.2 Validation Methods 
This validation includes two groups of women (see Figure 1.1). The original 
group was selected via random sample of women over the age of 18 who had an initial 
consultation for subfertility generally, or in vitro fertilization (IVF) specifically at the 
UCRM in the year 2004. Women who completed the online questionnaire were contacted 
by telephone for the follow-up interview at a time of their convenience to conduct the 
telephone component of the FEQ. The follow up interview typically occurred within 2 
weeks of completion of the written survey.  Medical records were then obtained from the 
UCRM for independent chart review to extract key variables for comparison.  Records 
from any other clinics that patients may have visited in addition to UCRM were not 
available to us for analysis. For the validation, we chose the following variables to 
compare between the medical chart review and the FEQ: use of oral ovulation enhancing 
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drugs, use of injectable ovulation drugs, use of IUI, use of IVF, time at risk of pregnancy, 
time to conception, pregnancy, and live birth. These represent the outcomes of greatest 
interest for this questionnaire. 
 We performed correlation analyses to determine the degree of agreement between 
the specified elements in the FEQ and the patients’ medical records.  For categorical 
variables (history of different types of treatment and pregnancy history), we calculated 
sensitivity and specificity, and used the kappa statistic to rate interobserver agreement. 56   
 
1.4.3 Treatment history 
The agreement between the FEQ and the medical record for different treatments is 
shown in Table 1.4. Compared to the medical record, the sensitivity of the FEQ was 
uniformly higher than specificity. The agreement was good for IUI and ART (kappa 0.64, 
95% CI 0.46-0.83; and 0.74, 95% CI 0.57-0.90, respectively), but lower for use of oral 
ovulation drugs and injectable ovulation drugs (0.41, 95% CI 0.21-0.61 and 0.21,95% CI 
0.0-0.51, respectively).  
 
1.4.4 Pregnancy history 
The kappa for the agreement for pregnancy history during the time the woman 
was a patient at the clinic was 0.65.  There was perfect concordance for 50 (79.4%) 
participants with respect to the number of pregnancies reported in the interview with the 
number of pregnancies reported in the medical record.  Nine women (14.3%) reported 
more pregnancies in the interview than were reported in the medical record, while one 
(1.6%) reported one fewer pregnancy in the interview than was reported in the medical 
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record.  The kappa for the agreement between live births a woman had during the time 
she was a patient at UCRM and what she reported was 0.55.  Forty-three (68.3%) showed 
perfect concordance, while 12 (19%) reported more live births in the interview than in the 
medical record and one (1.6%) women reported one fewer live birth in the interview than 
in the medical record.   
 
1.4.4 Time at risk of pregnancy and to time to conception 
 About half of the medical records did not contain sufficiently detailed information 
on time attempting to conceive at the first visit. We were able to compare and calculate 
time at risk of pregnancy for 35 women and time to conception for 29 of those women. 
The mean and median time at risk for pregnancy, as reported in the interviews was 42.1 
months and 40 months, respectively; in the medical record it was 36.4 and 30, 
respectively, with a Pearson’s correlation coefficient of 0.42 (95% CI 0.10-0.66) (Table 
1.5).  For time to conception, the Pearson’s correlation coefficient was 0.77 (95% CI 
0.55-0.88. 
In this validation study, we found that women’s responses to the FEQ were 
reasonably comparable to medical records for total time at risk of pregnancy, time to 
conception, pregnancy, live birth, and the use of IVF and artificial insemination. 
However, there was poor correlation between the FEQ and medical records for the use of 
oral or injectable ovulation drugs. Uniformly, sensitivity was higher than specificity, 
meaning that women reported many treatments or events that were not found in the 
medical record. This may mean that some women may have obtained treatments from 
physicians outside of the UCRM at the same time that they were also being seen at 
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UCRM, that women did not recall the timing correctly for treatments that were used 
before or after their time at UCRM, that women misunderstood what was meant by the 
questions (despite the fact that examples were given), or it may mean that the use of some 
treatments was not completely recorded in the medical record. Underreporting in the 
medical record of treatments actually given at the UCRM is possible for drugs, but we 
believe it is much less likely for procedures such as artificial insemination or IVF. 
Although there was substantial agreement in regards to pregnancies a woman 
achieved while as a patient in the clinic, nine (14%) of the women interviewed reported 
having more pregnancies at the time they were patients at UCRM than those recorded in 
their medical record. This is consistent with the fact that after receiving fertility treatment 
at the UCRM, some women go to their own OB/GYNs, family physicians, or midwives 
to confirm a pregnancy and receive prenatal care (since prenatal care is not provided at 
the UCRM). Unless there is some subsequent contact between the women and the 
UCRM, these pregnancies do not end up in the UCRM records. During this time period, 
there was routine follow-up from UCRM to women or couples undergoing IVF, but not 
necessarily for women undergoing other types of fertility treatment.  Probably for the 
same reasons, many women who had live births reported more live births in their 
interviews than what was found in their medical record at the UCRM. Additional 
validation studies that allow linkage to medical records of all providers seen, or perhaps 
complete visit and pharmacy billing records, are needed to corroborate our hypothesis 
that women reported additional fertility treatment and care for pregnancy outside of the 
single specialty clinic studied. 
In the development and pilot testing of the FEQ, we found that a combination of 
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written or online questions, followed by a clarifying telephone interview seemed to 
assure adequate understanding of the concept of “attempt to conceive.” While this makes 
the mixed-mode FEQ more resource-intensive to administer than an online-only (or 
written-only) questionnaire, we expect it may be worthwhile to collect this detailed 
information on time at risk of pregnancy. While TTP assessed retrospectively may be 
subject to recall bias, others have shown that the reliability of TTP recall is enhanced 
when women are queried in-person or via telephone or e-mail.54,57,58 We believe this 
supports the value of the two-stage approach to assessing TTP we have employed in the 
FEQ.  
We believe that the FEQ captures a more accurate and complete time at risk of 
pregnancy (called “attempts to conceive” in the FEQ) than the single measure of time 
“trying to conceive” reported in the woman’s medical record, as evidenced by the 35 
(52%) women in our sample that reported multiple attempts in the time leading up to the 
first clinic visit (for which the clinic visit identified only one “time trying” to conceive).  
 
1.5 Description of Population and Clinic Cohorts 
A total of 26,007 letters were sent, 15,400 for population recruitment and 10,677 
for clinic recruitment. There was no response to 22,758 (87%) of the letters and only 153 
(<1%) refused participation without screening. A total of 3,166 (12%) replied as 
interested in learning more about the study. Nearly all (96%) interested women were 
contacted for screening. Only 36% were eligible for participation based on living in Utah 
during the index period, not having any prior pregnancies, and trying to conceive for at 
least 12 months without conception. Of the 1105 eligible women, 87% (960) enrolled and 
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completed the online portion of the study. Table 1.6 describes the characteristics of all of 
the enrolled women by recruitment cohort. Although 903 women began the phone 
portion of the interview, only 837 completed all of the necessary parts. Figures 1.2 and 
1.3 show the recruitment flow for each of the recruitment cohorts.  
 
1.5.1 Description of Population Cohort 
A total of 501 women from the population recruitment cohort enrolled in FES. 
The majority of women were between the ages of 18 and 30 at their index date with only 
6% over the age of 30 and no one over the age of 35. Most women (95%) identified as 
white, non-Hispanic and either had some college or had graduated from college. The 
average longest attempt duration was 3.3 years (SD 2.8; median 3 years; range < 1 year-
16 years). Over half 53.5% had had a live birth by the time we interviewed them for the 
study. Using mutually exclusive categories to group women by their most invasive 
treatment: close to a third (31.3%) had never received any type of fertility treatment, 5% 
reported trying alternative treatments, 29% had used fertility drugs, 20% had used 
artificial insemination, and 14% had used IVF.  
 
1.5.2 Description of Clinic Cohort 
A total of 459 women from the clinic recruitment cohort enrolled in FES. Women 
recruited from the clinic were older on average than those from the population (p < 
0.001). Most women (93%) identified as white, non-Hispanic and either had some 
college or had graduated from college. The average longest attempt duration was 4.2 
years (SD 3.4; median 3 years; range < 1 year-18 years). Over half 58% had had a live 
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birth by the time we interviewed them for the study, and women from the clinic cohort 
reported close to double the number of multiple births (14.4% compared to 6.6% from 
population; p < 0.001). Using mutually exclusive categories to group women by their 
most invasive treatment: Only 6.5% had never received any type of fertility treatment and 
1.7% reported trying alternative treatments, 15.9% had used fertility drugs, 29% had used 
artificial insemination, and 47.3% had used IVF.  
 
1.6 Overall Motivation and Summary of Chapters 
The data from the Fertility Experiences Study provide in-depth detail on 
reproductive histories of a cohort of subfertile women. The novel recruitment approach 
fills a gap in current approaches to fertility research that involves women who may not 
have been seen in fertility clinics. The rich data allow for robust exploration into how 
women report their time at risk for pregnancy, nonmedical and medical treatments used 
during their reproductive history, and associations between fertility treatment and preterm 
births compared to subfertile women conceiving spontaneously.  
The duration of time attempting pregnancy, or time at risk of pregnancy (TARP), 
is central to the definition of infertility, but they can be defined and assessed in different 
ways. Aim 1 examines how women with a history of primary infertility recall their 
attempt duration or TARP, when asked with different questions. Misestimation of attempt 
duration could have important clinical implications. Understanding how women report 
TARP has the potential to improve the quality of data collected about pregnancy attempt 
durations in future research studies and to ensure appropriate management in clinical 
settings.59 Appropriate management could help avoid use of treatment with more 
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invasive, high-cost medical therapies such as IUI or IVF before such treatment is 
clinically warranted.6,60 Clinicians and researchers should recognize the limits of single 
question when assessing how long a couple has been having regular unprotected 
intercourse. Detailed attempt histories can capture a more detailed assessment of time at 
risk of pregnancy.  
Aim 2 describes use of behavioral, nonmedical, and medical interventions 
reported by women who experienced primary infertility. Women were asked about the 
use of interventions used to enhance fertility, either on their own or by recommendation 
of a doctor. Women were asked about the use of interventions used to enhance fertility, 
either on their own or by recommendation of a doctor. Interventions included fertility-
focused intercourse (by basal body temperature, cervical fluid, urine LH, and/or counting 
days); behavioral changes (weight loss, adherence to fertility diets); complementary and 
alternative medicine (CAM: vitamins, herbs, and/or acupuncture); and medical treatments 
(ovulation stimulation drugs (OS), IUI, and/or IVF with or without intracytoplasmic 
sperm injections (ICSI)). We also assessed male partner treatments in a subgroup of 
participants. This mix of medical and nonmedical interventions while trying to conceive 
has not been described previously. This is also one of the first studies to assess 
nonmedical interventions engaged in by the male partner of the subfertile couple.  
Aim 3 examines the effect of fertility treatment OS alone, IUI usually with OS, 
and IVF on PTB, compared to no treatment in subfertile women. While some providers 
advocate that IVF should become a primary management strategy for couples without 
specific indications because of its high probability of success per cycle success, there are 
substantial concerns about expanding use of IVF, including high cost and impact on 
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neonatal outcomes.15,16 Epidemiologic studies have demonstrated higher incidence of 
PTB, LBW, and birth defects among children conceived through IVF, when compared to 
children conceived naturally, even when the analyses are limited to singleton 
pregnancies.21,23,61 Additional questions remain as to whether these adverse outcomes are 
related to the treatments or to the underlying causes or severity of the subfertility.21,22 
Few studies exist that assess the independent risks of subfertility.23 Aim 3 provides 
insight into the relationship between fertility treatments (OS, IUI, and IVF) and preterm 
birth among women with primary subfertility compared to subfertile women who 
conceived without fertility treatment. We used data from parallel clinic and population-
based cohorts and examined the contribution of pregnancy attempt duration and fertility-
related diagnoses, as well as the role of multiple gestations. 
The final chapter will summarize key findings from the three aims, discuss 










Table 1.2 Final eligibility criteria for both the clinic cohort and the population cohort 
Age 20-35 at index date  
     Clinic cohort: date of first clinic visit  
     Population cohort: (a) December 31, 2004, or (b) December 31, 2008 
No pregnancies prior to index date  
At least one year of trying to get pregnant with male partner at index date 





New patient for infertility at UCRM in 2004 or 2008; or RCC between 2000-2009 
Patient has a male partner 
Age 20-34 at first visit (UCRM only) 
No known pregnancies prior to first appointment at clinic (UCRM only) 
 
Population Cohort (consists of two period subcohorts (a) and (b)) 
Married between (a) January 1, 2000, and December 31, 2002, or (b) between January 
1, 2004 and December 31, 2006 
Age 18-30 at date of marriage 
Married 2-5 years to same person as of (a) December 31, 2004, or (b) December 31, 
2008 
Husband living as of (a) December 31, 2004, or (b) December 31, 2008 
No Utah live births or fetal deaths as of (a) December 31, 2004, or (b) December 31, 
2008 
Current Utah address within the past 5 years  
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(paper or online) 
Phone interview 
component 
General health X  
Menstrual history X  
Sexual history X  
Pregnancies and attempts to 
conceive 
Definitions and 












Fertility-related diagnoses X  
Fertility-related surgeries X  
Fertility treatments used, 
and reasons for choosing or 




and linking timing to 
attempts to conceive 
Self-help measures for 
trying to conceive (fertility 
awareness, diet, etc.) 
 
Ascertained and 
linked to attempts to 
conceive 
Experience of fertility 
treatment 
X  
Stress and social situation X  
Adoption experiences X  
Demographic information X  
Friends and family with 
infertility 
X  
Wantedness of pregnancies 
prior to conception 
 X 
Hypothetical interest in 















Table 1.4 Agreement between medical record review and FEQ interview for fertility 
treatments, and sensitivity and specificity of the FEQ interview, considering the medical 
record as the gold standard 
 







  Interview    
   Yes No 






Medical Record  Yes 21  2     
 No 17 21    
       
Ovulation drugs, 
injectable      
  Interview    







Medical Record Yes 23 10    
 No 12  16    
       
Intrauterine insemination      
  Interview    
   
 
Yes No 






Medical Record Yes 25 2     
 No 9 25    
       
In Vitro 
Fertilization       
  Interview    







Medical Record Yes  23 1     
 No  7 30    
Pregnancy       
  Interview    
   Yes No 






Medical Record Yes  32 1    
 No 9 18    
 
Live Birth        
  Interview    







Medical Record Yes 22 1     
 No 12 21    
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Table 1.5 Correlation between medical record review and interview for duration of time 
at risk of pregnancy and time to conception 
 
 











Time at risk of 







record  36.4 (21.7) 
30 
5-96  
Time to conception, 












Table 1.6 Characteristics of enrolled women (N = 960) 
  Clinic Population Total p-value 
  N % N % N %   
Age At Index Date             0.000 
18-<25 206 56.9% 317 73.2% 523 65.8%   
25-<30 110 30.4% 107 24.7% 217 27.3%   
30+ 46 12.7% 9 2.1% 55 6.9%   
Annual Income             0.000 
Less than $50,000 112 25.6% 180 37.3% 292 31.7%   
$50,000-$99,999 247 56.4% 259 53.7% 506 55.0%   
Over $100,000 79 18.0% 43 8.9% 122 13.3%   
Education Level             0.298 
Less than college graduation 163 35.7% 195 38.9% 358 37.4%   
College graduation or more 294 64.3% 306 61.1% 600 62.6%   
Race/Ethnicity             0.200 
White 425 92.6% 474 94.6% 899 93.7%   
Hispanic, Other Non-White 34 7.4% 27 5.4% 61 6.4%   
Religious Affiliation             0.081 
Latter-day Saint 121 26.4% 108 21.6% 229 23.9%   
Non-LDS 338 73.6% 393 78.4% 731 76.2%   
Maximum Insurance              0.000 
None or unsure 32 7.4% 59 13.6% 91 10.5%   
Diagnostic and/or Treatment 100 23.1% 172 39.6% 272 31.4%   
Not Asked 301 69.5% 203 46.8% 504 58.1%   
BMI Category             0.276 
Underweight/Normal 220 52.3% 223 48.6% 443 50.3%   
Overweight/Obese 201 47.7% 236 51.4% 437 49.7%   
Ever Pregnant              0.034 
No 117 44.0% 149 32.8% 266 29.6%   
Yes 328 51.7% 306 67.3% 634 70.4%   
Ever Live Birth              0.019 
No 156 35.1% 193 42.7% 349 38.9%   
Yes 289 64.9% 259 57.3% 548 61.1%   
Highest Treatment (Screen)             0.000 
None 43 9.4% 207 41.3% 250 26.0%   
Ovulation Drugs 63 13.7% 128 25.6% 191 19.9%   
IUI 142 30.9% 97 19.4% 239 24.9%   
IVF 211 46.0% 69 13.8% 280 29.2%   
Longest duration (screen)             0.068 
12mo-<24months 55 31.3% 84 16.8% 139 14.5%   
24mo-<48months 155 33.8% 154 30.7% 309 32.2%   
48mo-<60months 50 10.9% 65 13.0% 115 12.0%   
More than 60 months 195 42.5% 185 36.9% 380 39.6%   
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A COMPARISON OF THREE APPROACHES TO COLLECTING DATA ON 
PREGNANCY ATTEMPT DURATION AMONG WOMEN WITH A  





The duration of time attempting pregnancy, or time at risk of pregnancy (TARP), 
are central to the definition of infertility (or subfertility), but they can be defined and 
assessed in different ways. The aim of this study is to examine how women with a history 
of primary subfertility recall their attempt duration or TARP when asked with different 
questions. 
The Fertility Experiences Study (FES) is a retrospective cohort study of women 
with primary subfertility conducted at the University of Utah between April 2010 and 
September 2012. Questions about pregnancy attempt duration were repeated over the 
course of the FES at different times using three different approaches: a single question, a 
series of specific questions about dates (date approach), and a question about dates of 
“actively trying.” 
We found significant discrepancies in reported attempt duration between the three 




duration based on a single question, as compared to information obtained using the date-
based approach (+/- 3 months), while 37% of women overestimated and 29% of women 
underestimated their TARP with the single question. However, for a 24-month threshold, 
the single question was over 90% correct compared to the date-based approach. Asking 
about the date of actively trying resulted in shorter attempt durations.   
Clinicians and researchers should recognize the limits of single question when 
assessing how long a couple has been having regular unprotected intercourse. Detailed 




One in seven couples will experience difficulty conceiving at some point in their 
reproductive lives.1, 2 The International Committee for Monitoring Assisted Reproductive 
Technology (ICMART) define infertility as a disease of the reproductive system resulting 
in the failure to achieve a clinical pregnancy after 12 months of regular unprotected 
sexual intercourse.3 This definition of infertility—as failure to achieve pregnancy after 12 
months with unprotected intercourse has been widely used in both research and clinical 
settings. Although the term infertility is frequently used to describe the clinical condition, 
the use of the term subfertility may be more accurate in expressing the spectrum of 
fertility that many couples experience. Subfertility will be used for the purposes of this 
manuscript.   
 Pregnancy “attempt duration” is an important concept as it is central to how 
subfertility is defined and diagnosed. Extended attempt duration it also an independent 
predictor of more severe subfertility and of adverse pregnancy outcomes.4 When 
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examining fecundity (defined as the biologic capacity to reproduce) it is important to 
consider that many couples will successfully conceive without medical treatment even 
after meeting the criterion for clinical subfertility. Among couples with unexplained 
subfertility, an estimated 43-60% of those who fail to conceive during the first 12 cycles 
will achieve conception after an additional 12 cycles of trying, depending on age.5 
Therefore, the World Health Organization (WHO) has recommended using a definition of 
subfertility of 24 months of unprotected intercourse to reduce the number of individuals 
who are “falsely” diagnosed with fertility problems.6 Beyond the 24 months there is still 
a small potential for spontaneous conception without medical assistance.3, 7 However, 
couples who do not conceive after 48 months of properly timed intercourse have more 
severe subfertility, and the likelihood of spontaneous conception without treatment drops 
to only 5%.7  
Given that attempt duration is a central component of subfertility diagnosis, 
differences in how researchers and clinicians collect data on biological “time at risk for 
pregnancy” (TARP), intentional pregnancy attempt duration, or behavioral time 
“actively” trying to conceive can influence key findings in the field and how clinical 
management proceeds. Additionally, all of the measures of pregnancy attempt duration 
are patient-reported and therefore subject to typical biases including recall error, social 
desirability, and accuracy. Methods should be addressed to reduce these biases. There has 
been movement among the scientific community to increase the monitoring of fertility 
using more direct and consistent measures of biological TARP rather than measures of 
“trying to conceive” which implies intention.8-10 
Understanding how women report TARP has the potential to improve the quality 
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of data collected about pregnancy attempt durations in future research studies and to 
ensure appropriate management in clinical settings.11 Appropriate management could 
help avoid use of treatment with more invasive, high-cost medical therapies such as 
intrauterine inseminations (IUI) or in vitro fertilization (IVF) before such treatment is 
clinically warranted.12, 13 Additionally, identifying characteristics of women who 
substantially misestimate (either over- or underestimate) TARP may provide insight on 
the reliability of single question approaches frequently used in clinical practice and the 
potential for bias caused by differential misclassification of the severity of subfertility for 
women reporting fertility histories. 
The aim of this study is to compare longest pregnancy attempt recall based on 
three different questioning approaches among women with a history of subfertility. The 
first approach uses a standard single question (single question approach); the second 
approach is a series of questions assessing discrete pregnancy attempts using specific 
dates for start and stop time at risk (date approach), and the third approach asks the 
woman for a date when she began “actively” trying to become pregnant (active date 
approach). In this study, the date (second) approach is used as the “gold standard” for 
TARP and used to compare to the other approaches. We hypothesize that women 
frequently misestimate TARP when using a single question approach, as compared to the 





The Fertility Experiences Study (FES) is a retrospective cohort study conducted at 
the University of Utah between April 2010 and September 2012. The FES cohort was 
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developed with the intention of identifying women with primary subfertility who may or 
may not have received clinical diagnosis or medical treatment. Women were recruited 
from fertility clinics as well as from the general population. The clinic-based cohort was 
recruited from two specialty fertility clinics in Utah. For clinic recruitment, invitations 
were mailed to all women who had initial clinic visits during the index years of 2004 and 
2008.  The population-based cohort was identified using a unique research resource 
called the Utah Population Database (UPDB). The UPDB is a database that links vital 
records and medical records and provides access to present and historical information on 
over 7 million individuals.  Using the UPDB, we were able to sample state marriage 
records without linked birth certificates or fetal death records within two years of their 
marriage. Recruitment of the population-based group was facilitated by the Resource for 
Genetic and Epidemiologic Research (RGE) to maintain the privacy of individuals and 
confidentiality of data belonging to women who were not interested in enrolling. RGE 
mailed letters and followed up with telephone calls to inform potential participants about 
the study. Interested individuals from both the population and clinic recruitment were 
screened for eligibility. The parallel clinic-based and population-based cohorts consist of 
women residing in Utah with a history of primary subfertility  (i.e., trying to conceive for 
at least 1 year, with no prior pregnancies) as of a specified index date between 2004 and 
2008. Women from both cohorts were screened for eligibility. Women determined to be 
eligible were then invited to complete a self-administered online questionnaire (or paper, 
if requested). Upon completion of the self-administered questionnaire, trained study staff 
conducted an in-depth phone interview. Upon completion of the study participants 
received a $10 gift card. A multidisciplinary team of clinicians and researchers developed 
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both the self-administered questionnaire and the phone interview tool. The questionnaire 
was validated using a sample of clinic-recruited women prior to initiating the study. 
Questionnaire data on pregnancy attempt duration, medical treatment, attempt outcomes, 
and pregnancy outcomes were compared with medical records from one of the specialty 
clinics the Utah Center for Reproductive Medicine (UCRM). Compared to the medical 
record, the Fertility Experiences Questionnaire (FEQ) was over 90% sensitive for all 
elements, except injectable ovulation drugs (70% sensitivity). The FEQ accurately 
captured many elements of fertility treatment history at 5-6 years after the first visit to a 
specialty clinic. The University of Utah Institutional Review Board approved this study. 
The three different approaches to assessing pregnancy attempt duration were 
based on different questions asked at different times during the study. The first approach, 
used during the participant screening process, was designed to identify women who may 
have experienced primary subfertility with a single question. This “single question 
approach” question was worded “What was the longest period of time where you were 
not doing anything to prevent pregnancy but did not get pregnant?” The second approach, 
“the date approach,” asked about specific dates when participants were at risk for 
pregnancy, defined as time intervals when they were having sexual intercourse with a 
man without using any method to prevent pregnancy. The date approach was designed to 
identify more precise time periods when a woman was biologically at risk for pregnancy 
and to exclude periods when she was using birth control or was not heterosexually active 
for any reason. Pregnancy attempts started when the woman started becoming 
heterosexually active without birth control, or simply stopped using birth control. 
Pregnancy attempts could end in pregnancy, use of birth control, separation or divorce 
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from partner, or abstinence from intercourse for any other reasons. These questions were 
asked in the online survey and then repeated and verified during the telephone interview. 
A third approach, “the active date approach,” was asked during the telephone interview 
to specify when couples were actively trying to conceive. This approach asked women 
“Was there a point during this attempt when you ‘actively’ started trying to get pregnant? 
What date did you actively start trying to get pregnant?” The active attempt duration used 
the same end date as described in the second approach. For the purpose of this analysis, 
each discrete attempt was assessed to determine longest discrete pregnancy attempt 
durations. Only the longest reported duration was used in the analysis as a comparison to 
the single item question.  
Descriptive analysis was performed to determine characteristics of women who 
substantially misestimated their longest reported TARP with the use of the single 
question approach, as compared to a date-based approach (considered the “gold standard” 
for this analysis). Substantial misestimation was defined as a difference of 3-months or 
more between the single question and date-based approach. Participant characteristics 
examined were recruitment pool (population or clinic), months since first pregnancy 
attempt began, having a pregnancy or live birth during the follow-up period of the study, 
participant utilization of memory aids (including medical chart, journals, or diaries) 
during data collection, self-perception of subfertility, and sociodemographic 
characteristics (age at study index, BMI, income, education, race/ethnicity, and religious 
affiliation). Pearson’s chi-squared tests were used to assess the proportion of women 
misestimating TARP by different characteristics. A multinomial logistic regression 
analysis was conducted to calculate unadjusted and adjusted relative-risk ratios (RRR) to 
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separately estimate the risk of TARP overestimation and TARP underestimation 
associated with a variety of factors. Potential confounders, including recruitment site, 
age, BMI, education, and religious affiliation, and months between attempt initiation and 
date of interview were determined a priori and were adjusted for in all multivariable 
models to determine adjusted relative-risk ratios (aRRR). We developed three models to 
assess the relative risk of TARP misestimation: Model 1 included recruitment site, age, 
BMI, education, and religious affiliation, as well as months between the date of the first 
attempt initiation (based on the date approach) and interview; Model 2 included all 
aforementioned variables in addition to pregnancy outcomes; and Model 3 included 
previous covariates and the most invasive fertility treatment used during all pregnancy 
attempts.  A sensitivity analysis was conducted limiting to longest durations that were 
reported as first attempts only. 
Additional analyses were conducted to examine the variation in TARP reported 
by the participants in the FES study using all three approaches to assess the single longest 
attempt duration. A Pearson’s correlation is used to examine the relationship between the 
single question approach, the date approach, and the active date approach. Distributions 
of the single longest reported attempt durations from each of the three questions 
approaches were examined with regard to different thresholds for subfertility: subclinical 
(<12 mo), clinical (≥12 mo), WHO recommendation  (≥24 mo), and more severe 
subfertility  (≥ 48 mo). Sensitivity and specificity for the three approaches were used to 









A total of 960 women enrolled in FES: 501 women were recruited from the 
population and 459 women were recruited from fertility clinics. Completion rates were 
good, with 886 (92%) women completed both the online survey and the phone interview. 
Of women who completed the study, 19 women were dropped from the analysis due to 
missing attempt data; four of these women had dates that were improperly formatted in 
the database, and 15 women had missing attempt end dates but had not reported that they 
were “still trying to conceive.” A total of 867 women were retained for data analysis. 
Figure 2.1 describes the participant flow for the study and analysis.  
Women recruited from the fertility clinics were on average 5.4 years older at the 
index date compared to women recruited though the population (p < 0.001).  Women in 
the clinic cohort were also 1.4 years older at the time of their first attempt than women 
recruited form the population (25.8 ± 4.8 years versus 24.4± 3.1years; p < 0.001). In 
addition, women from the clinic-cohort reported longer attempt durations with both the 
single approach and the dated approach compared to the population-cohort. Clinic 
recruited women reported an average of 60.4 months ± 42 months using the single 
question approach and 58.7 months ± 41 months using the dated approach (p < 0.001). 
Population recruited women reported an average of 50.9 months ± 32 months using the 
single question approach and 45.2 months ± 32 months using the dated approach (p < 
0.001). Women recruited from the clinic also had a significantly longer time between the 
dates that their first attempt started and when the date the interview was conducted in 
comparison with women recruited from the population (mean 102 months ± 55 months 
versus 76 months ± 31 months, respectively; p-value < 0.001).  
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Most women (82%) reported their single longest attempt began when they first 
initiated regular intercourse without contraception. There was a statistically significant 
difference in longest TARP reported using the single question approach compared with 
the date-based approach. The mean longest single attempt duration was on average 4.5 
months longer using the single question compared to the date-based approach (56 months 
± 38 versus 52 months ± 38; p-value < 0.001). Overall, women from both recruitment 
pools overestimated their longest TARP using the single question approach. Women 
recruited from the clinic overestimated by an average of 1.8 months (± 29 months), while 
population-recruited women overestimated by 5.7 months (± 26 months; p-value = 0.04).  
Over half of the women enrolled in the study had at least one pregnancy ending in 
a live birth, and 13/49 (26.5%) of the women who had a pregnancy without a live birth 
were still pregnant at the time of the phone interview. Over two thirds of women who did 
not achieve a pregnancy (292/435) were still attempting pregnancy at the time of the 
interview, the remaining third had not achieved pregnancy but reported that they were no 
longer trying to conceive. Women who never achieved a pregnancy had the longest 
average single attempt of 71 months ± 42 months, followed by those having pregnancy 
without a live birth (including women who were pregnant during the interview) 45 
months ± 29 months using the date approach. Women who had a pregnancy that resulted 
in a live birth had the shortest average longest pregnancy attempt duration (40 months ± 
29 months) using the date approach. 
Table 2.1 displays the proportion of women who accurately reported their TARP 
on the single question and those who either over or underestimated their TARP by more 
than 3 months (using the date-based questions as a gold standard) for different 
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characteristics of the women. Many women in the study  (37%) overestimated their 
longest TARP with the single item approach, about a third (34%) estimated their longest 
attempt duration accurately using the single question (within 3 months of the date 
approach), and 29% underestimated their longest attempt duration with the single 
question. Unadjusted relative risk ratios for associations between misestimating TARP by 
more than 3 months are reported in Table 2.2. Women who accurately reported their 
longest TARP and those who misestimated longest TARP differed by recruitment site, 
age at index, BMI, education level, religious affiliation, attempt outcomes, length of time 
between start of first attempt and time of interview, and most invasive fertility treatment 
ever used. 
 In the adjusted analysis, the expected risk of under- and overestimating longest 
TARP was increased for each year older women were at the time of their first attempt 
(RR 1.88 [95% CI 1.27-2.79] and RR 1.04 [95% CI 1.00-2.04], respectively).  Women 
who were overweight or obese were also at an increased risk of overreport TARP than for 
women who were either normal weight/underweight (RR 1.44 [95% CI 1.01-2.05]). 
Women who completed college had a lower risk of overestimation, RR 0.64 [95% CI 
0.43-0.93], or underestimation, RR 0.57 [95% CI 0.37-0.87], than women with lower 
educational levels. Women who had longer intervals between the start of their first 
attempt and were at an increased risk of overestimating their longest attempts for each 
additional year between their first attempt and the interview, aRRR 1.01 [95% CI 1.00- 
1.02]. Women who had IVF were also at an increased risk of overestimating their attempt 
duration compared to women who had any other treatment or no treatment at all aRRR 
1.62 [95% CI 1.08-2.44] (Table 2.3). 
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The Pearson’s correlation between TARP reported by the single question 
approach versus the date approach was 0.73. Using the single question approach and a 
time trying criterion of 24-months (based on the WHO recommendations) as a cutoff for 
a diagnosis of subfertility, the sensitivity of the single question approach was 97.5% and 
the specificity was 56.8%, resulting in 88% being correctly classified as infertile. When 
using a 48-month cutoff, the single item approach had a 90.4% sensitivity and a 76.7% 
specific, resulting in 82% being correctly identified as severely infertile. We could not 
assess for the 12-month cutoff because women with less than 12 months on the single 
question approach (on the screening questionnaire) were excluded from the study. 
The distribution of attempt duration by each method of questioning, divided into 
four categories, is seen in Figure 2.2, and continuous in Figure 2.3. The active-date 
approach defined shorter active attempt durations compared to both the single question 
and the study gold standard date approach. Of the 867 women, 688 (79%) indicated that 
they “actively” started trying to conceive at some point during the period where they 
were at risk for pregnancy.  The Pearson’s correlation between the active-date approach 
compared with the date-based approach was 0.80. Using the active approach as the gold 
standard and the classic 12-month cutoff for subfertility, the sensitivity was 100% and the 
specificity was 24.4%, with 90% of cases correctly classified as infertile by the date 
approach. Sensitivity and specificity for all questions can be seen in supplemental tables 
2.4-2.6. A total of 13.3% of women would be identified as not yet having met the cutoff 
for subfertility  (<12 months) using the active date approach compared to the date-based 
approach.  
To ensure that there was no systematic errors occurring due to intervening breaks 
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in attempts, we conducted a sensitivity analysis limited to longest attempts that were also 
first attempts. Eighty-two percent of single longest reported attempts were first attempts. 
The multinomial logistic regression had similar findings. The correlation between the 
date-approach and the single improved slightly (0.75) when limiting to first attempts but 





We found that misestimation of longest single attempt duration occurred 
frequently when information was solicited using the common single question approach. 
Only a third (34%) of women accurately reported their longest attempt duration based on 
this single question when compared to information obtained using the date-based 
approach (+/- 3 months), while 37% of women overestimated and 29% of women 
underestimated their TARP using the single question approach. Women who 
overestimated their longest attempt with the single question approach were older when 
their first attempt started, had higher BMIs, and had longer time intervals between their 
first attempt and the time of the interview. Women who underestimated their TARP were 
older when their first attempt started, had lower educational attainment, and had a longer 
time interval between the start of their first attempt and the date of the interview. The risk 
of misestimation was significantly lower for women who had experienced a pregnancy 
(with or without live birth). This may be due in part to an isolation effect and the fact that 
they have a specific event to link the end of their pregnancy attempt. The sensitivity and 
specificity of the single question for capturing a person who had been trying for 24 
months was good with over 90% being correctly identified as infertile using the 24-
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month cutoff.  
A strength of this study is the population studied, which included women with 
primary subfertility recruited through fertility clinics in addition to women recruited 
through population-based sampling. The design of this study excluded women with self-
reported attempt durations of less than 1 year (based on a single question approach) and 
therefore is not generalizable to women who do not self-identify as having been at risk 
for pregnancy for less than 1 year.   
There are a number of limitations of this study. It is retrospective and may be 
subject to recall bias. There may have also been some “learning” effect of being asked to 
report attempt durations multiple times over the course of the study; however, we used a 
calculated duration from the date-approach that we did not report back to the woman, and 
this may have attenuated the potential for attention bias. We believe the date-based 
approach used during the in-depth phone interview was the best measure available in this 
study, as trained study staff checked for chronology of events and were able to answer 
any questions that the participant may have had about what constituted the beginning and 
end of a discrete attempt. In absence of prospective study, however, we cannot say with 
certainty which of these approaches elicits the “correct” response. Still, the variability in 
responses to the three question approaches calls into question research findings or 
diagnoses that are based on just one of the three measures. Future research should explore 
differences in reporting of biological TARP and “active” behavioral time trying to 
conceive in a prospective manner in order to better understand the relationship between 
behaviors and attitudes toward pregnancy in infertile populations without telescoping 
effect or potential for recall bias. 
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The study of fertility and attempt duration is fraught with subjectivity. This study 
describes differences in retrospective measures of biological time at risk for pregnancy 
and reports of intentional pregnancy attempt durations obtain through different 
questioning approaches.   We believe these findings highlight the value of taking a 
detailed attempt history using a date-based approach. The finding that women who 
experienced a pregnancy (regardless of live birth) were better at recalling attempt 
duration supports the use of a life event history framework.14 The findings of this 
research also caution against assuming that biological TARP is equivalent to what is 
commonly referred to as “trying to conceive,” which is imbued with intentionality, or that 
either of these measures can be determined using a single question. A variety of issues 
may affect how attempt duration is reported and the way in which the question regarding 
attempt duration is asked affects the answer. Additionally, in 2013, The Practice 
Committee of the American Society for Reproductive Medicine updated the definition of 
subfertility to include the phrase “12 months or more of appropriately timed 
unprotected intercourse or therapeutic donor insemination.” This should be incorporated 
into questions assessing pregnancy attempt duration. Variations can cause bias in self-
reports of time trying to conceive, skew fertility prognosis, and alter treatment plans. The 
percent of women who had yet to reach the WHO recommended 24-month threshold 
increased from the single question approach to the date-based approach (and increased 
even further when using the active attempt approach). Although unavailable in the 
current dataset this is likely to be the case for the 12-month cutoff as well. Physicians, in 
primary care and specialty settings, should avoid the use of a single question when 
assessing how long a couple has been having regular unprotected intercourse. Detailed 
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attempt histories should be used to capture a more accurate and complete picture of “time 
trying to conceive,” including reports of the number of cycles using “fertility focused 
intercourse.”   Providers should also understand the potential impact of inaccurate 
pregnancy attempt reporting on patient treatment recommendations, which can 
unnecessarily increase patient’s risk for undergoing potentially unnecessary treatments, 




Table 2.1 Participant characteristics by accuracy of reporting attempt duration by single 
question, as compared to date approach (N = 867) 
 
Single question >3mo 
UNDER date approach 
Single question 
accurate (within 3 mo.) 
Single question >3mo 
OVER date approach P-value 
 
N Row% N Row% N Row% 
 Recruitment Site 
       Clinic 146 34% 129 30% 158 36% 0.002 
Population 103 24% 168 39% 163 38% 
 Age at first attempt 
       ≤25 146 28% 192 37% 185 35% 0.223 
26-30 53 24% 79 36% 85 39% 
 31+ 22 40% 16 29% 17 31% 
 Age at Index 
       18-25 64 21% 134 44% 104 34% 0.000 
26-30 77 27% 103 36% 110 38% 
 31+ 80 39% 50 25% 74 36% 
 BMI Category 
       Underweight 4 19% 11 52% 6 29% 0.007 
Normal 91 24% 147 39% 141 37% 
 Overweight 62 31% 65 32% 75 37% 
 Obese 66 34% 46 24% 80 42% 
 Annual Income 
       Less than $50,000 65 25% 102 39% 95 36% 0.370 
50,000-$99,999 136 30% 157 34% 165 36% 
 Over $100,000 30 27% 34 31% 47 42% 
 Education Level 
       Less than college grad 98 32% 90 29% 122 39% 0.045 
College grad or more 149 27% 207 37% 199 36% 
 Race/Ethnicity 
       White, Non-Hispanic 227 28% 282 35% 306 38% 0.081 
Hispanic, Other Non-White 22 42% 15 29% 15 29% 
 Religion 
       Non-LDS 71 35% 51 25% 83 40% 0.004 
Latter-Day Saint 178 27% 246 37% 238 36% 
 Insurance 
       None or unsure 187 29% 222 34% 246 38% 0.806 
Some insurance coverage for 
Dx or Tx 62 29% 75 36% 74 35% 
 Highest attempt outcome 
       Live birth, multiple 22 24% 27 29% 43 47% 0.000 
Live birth, single 80 20% 154 39% 166 42% 
 No pregnancy 139 43% 97 30% 90 28% 
 Pregnancy, no live birth 8 16% 19 39% 22 45% 
 Time between start of 1st 
attempt and interview 
       <3years 9 12% 37 49% 29 39% 0.000 
3-<6years 58 22% 117 44% 92 34% 
 6-<10year 114 31% 118 32% 138 37% 
 10 years + 68 44% 25 16% 61 40% 
 Used Records 
       No 128 28% 167 36% 165 36% 0.138 
Yes 116 29% 130 33% 150 38% 
 Perceived Subfertility  
       No 27 28% 35 36% 35 36% 0.923 
Yes 222 29% 262 34% 285 37% 
 Most Invasive Tx  
       None 32 24% 50 38% 51 38% 0.002 
Alternative 13 42% 11 35% 7 23% 
 Drugs 46 26% 67 38% 63 36% 
 AI 52 25% 89 42% 69 33% 
 IVF 106 33% 80 25% 131 41% 
 Total 249 29% 297 34% 321 37%   
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Table 2.2 Unadjusted Relative Risk Ratios for associations between misestimating 






Underestimating >3months [95% 
CI] 
Recruitment Site 
  Clinic 1.26 [0.92, 1.73] 1.85 [1.31, 2.60] 
Population 1.00 [Reference] 1.00 [Reference] 
Age at first attempt* 1.00 [0.97, 1.05] 1.00 [0.96, 1.05] 
BMI Category 
  Underweight/Normal 1.00 [Reference] 1.00 [Reference] 
Overweight/Obese 1.50 [1.08, 2.09] 1.92 [1.34, 2.75] 
Annual Income 
  Less than $50,000 1.00 [Reference] 1.00 [Reference] 
$50,000-$99,999 1.13 [0.79, 160] 1.36 [0.92, 2.00] 
Over $100,000 1.48 [0.88,2.50] 1.38 [0.77,2.48] 
Education Level 
  Less than college grad 1.00 [Reference] 1.00 [Reference] 
College grad or more 0.71 [0.51, 0.99] 0.66 [0.46, 0.94] 
Race/Ethnicity 
  White, Non-Hispanic 1.00 [Reference] 1.00 [Reference] 
Hispanic, Other Non-White 0.92 [0.44, 1.92] 1.82 [0.92, 3.59] 
Religion 
  Non-LDS 1.00 [Reference] 1.00 [Reference] 
Latter-Day Saint 0.59 [0.40, 0.88] 0.52 [0.35, 0.78] 
Insurance Coverage of Dx 
or Tx 
  None or unsure 1.00 [Reference] 1.00 [Reference] 
Some ins. Coverage 0.89 [0.61, 1.28] 0.98 [0.67, 1.44] 
Longest attempt outcome 
  No pregnancy 1.00 [Reference] 1.00 [Reference] 
Pregnancy, no live birth 1.06 [0.61, 1.83] 0.38 [0.20, 0.73] 
Pregnancy, Live birth 0.75 [0.54, 1.05] 0.25 [0.17, 0.36] 
Time between start of 1st 
attempt and interview* 1.01 [1.00, 1.02] 1.02 [1.01, 1.02] 
Most Invasive Tx  
  None 1.00 [Reference] 1.00 [Reference] 
Alternative 0.62 [0.22, 1.74] 1.84 [0.73, 4.62] 
Drugs 0.92 [0.54, 1.55] 1.07 [0.60, 1.92] 
IUI 0.76 [0.46, 1.25] 0.91 [0.52, 1.60] 
IVF 1.60 [0.99, 2.59] 2.07 [1.22, 3.52]  






Table 2.3 Multinomial logistic regression of over or under estimation of duration from single question compared to gold standard. 
         Model 1 Adjusted Model 2 Adjusted Model 3 Adjusted RR 
Exposure OVER [95% CI] UNDER [95% CI] OVER [95% CI] UNDER [95% CI] OVER [95% CI] UNDER [95% CI] 
Recruitment Site             
Clinic 0.82 [0.56, 1.19] 1.13 [0.74, 1.72] 0.86 [0.59, 1.26] 1.13 [0.74, 1.76] 0.85 [0.56, 1.27] 1.21 [0.78, 1.95] 
Population 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 
Age at Index 1st attempt (years) 1.04 [1.00, 2.04] 1.88 [1.27, 2.79] 1.04 [0.98, 1.09] 1.04 [0.99, 1.11] 1.03 [0.98, 1.09] 1.04 [0.98,1.10] 
BMI Category             
Underweight/Normal 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 
Overweight/Obese 1.44 [1.01,2.05] 1.26 [0.83, 1.89] 1.41 [0.99, 2.02] 1.78 [1.18,2.68] 1.47 [1.02, 2.13] 1.89 [1.24, 2.88] 
Education Level             
Less than college grad 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 
College grad or more 0.64 [0.43, 0.93] 0.57 [0.37, 0.87] 0.65 [0.44, 0.97] 0.67 [0.43, 1.05] 0.66 [0.44, 0.98] 0.66 [0.42, 1.04] 
Religion             
Non-LDS 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 
Latter-Day Saint 0.68 [0.43, 1.07] 0.68 [0.42, 1.11] 0.74 [0.47, 1.16] 0.76 [0.46, 1.26] 0.73 [0.47, 1.17] 0.78 [0.47, 1.31] 
Months between first attempt 
and Interview Continuous 1.01 [1.00, 1.02] 1.01 [1.00, 1.02] 1.01 [1.01, 1.02] 1.01 [1.01, 1.02] 1.01 [1.00, 1.02] 1.01  [1.01, 1.02] 
Ultimate reproductive outcome             
No pregnancy     1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 1.00 [Reference] 
Pregnancy, no live birth     0.96 [0.53, 1.75] 0.30 [0.14, 0.66] 0.98 [0.53, 1.81] 0.32 [0.14, 0.67] 
Pregnancy, live birth     0.70 [0.48, 1.02] 0.23 [0.15, 0.36] 0.67 [0.45, 0.98] 0.22 [0.14, 0.35] 
Most invasive fertility 
treatment              
None         1.00 [Reference] 1.00 [Reference] 
Alternative only         0.49 [0.16, 1.52] 1.34 [0.47, 3.80] 
Drugs only         0.79 [0.43, 1.43] 0.61 [0.30, 1.23] 
Intrauterine insemination         0.58 [0.32, 1.07] 0.50 [0.25, 1.03] 






Figure 2.1 TARP participant flowchart 
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Figure 2.3 Distribution of longest reported duration between date approach and single 
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BEHAVIORAL, NONMEDICAL, AND MEDICAL INTERVENTIONS REPORTED 





The objective of this chapter is to describe the use of behavioral, nonmedical, and 
medical interventions reported by women who experienced primary infertility. A 
retrospective cohort study of women who experienced primary infertility in Utah between 
2000 and 2009 was developed.  Participants were recruited from specialty reproductive 
endocrinology clinics and the general population. Women were asked about the use of 
interventions used to enhance fertility, either on their own or by recommendation of a 
doctor. Interventions included fertility-focused intercourse (by basal body temperature, 
cervical fluid, urine LH, and/or counting days); behavioral changes (weight loss, 
adherence to fertility diets); complementary and alternative medicine (CAM: vitamins, 
herbs, and/or acupuncture); and medical treatments (ovulation stimulation drugs (OS), 
intrauterine insemination (IUI), and/or assisted reproductive technologies (ART) 
including in-vitro fertilization (IVF) with or without intra-cytoplasmic sperm injections 
(ICSI)). We also assessed male partner treatments in a subgroup of participants. 
The mean number of total interventions used by women was 3.4, range 0 to 8 




intercourse, most with multiple indicators of fertility. At least one type of CAM was used 
by 33% of women, and over 80% reported use of one or more medical treatments. 
Compared to women recruited from specialty infertility clinics, women from the general 
population were less likely to use any type of medical treatment, but equally likely to use 
nonmedical interventions. 
Women commonly use a mix of medical and nonmedical interventions while 
trying to conceive. Both primary care clinicians and fertility specialists should assume 
that nearly all their patients are using some type of nonmedical intervention and should 
take a full history that includes assessment of behavioral changes and interventions in 
complementary and alternative medicine.  
 
3.2 Introduction 
The majority of infertility research occurs in clinical settings where patients are 
actively seeking medical diagnosis and treatment. However, little is known regarding the 
use of nonmedical interventions intended to increase chances of conception used by 
women with extended pregnancy attempts.  In addition, the medical and nonmedical 
interventions used by women from the general population have not been described 
previously. Research defining infertility as regular unprotected intercourse without a 
resulting conception after 12 months or more finds the prevalence of infertility among 
women currently trying to become pregnant to be around 15% in the United States.1 For 
women who have never been pregnant before, this condition is referred to as primary 
infertility or subfertility.  
Women who have difficulty conceiving commonly seek medical diagnosis; about 
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half of women who suffer from subfertility seek medical treatment from a healthcare 
provider.2 About one in 10 women in the United States receive some type of medical 
fertility service.3  Medical interventions to treat infertility include ovulation stimulation 
medications (OS), intrauterine insemination (IUI), and assisted reproductive technologies 
(ART) including in-vitro fertilization (IVF).4 The most recent clinic surveillance of ART 
from 2012 reports close to 200,000 IVF cycles resulting in 51,267 live births in the 
United States.5 Births conceived during IVF cycles comprise over 1% of all births in the 
United States, and another 1% of live births result from IUI cycles.6 Estimating the use of 
ovulation enhancing drugs is more difficult as both primary care and specialty providers 
manage infertility using these medications, and there is no formal reporting system. 
However, it is estimated that OS accounts for up to 6% of the births in the United States.7  
  In addition to medical treatments, couples that are having difficulty conceiving 
may explore nonmedical or behavioral interventions. Some of these interventions have 
strong data supporting their effectiveness, while others need more research. Data exist to 
support the use of fertility-focused intercourse to increase per-cycle pregnancy rates in 
couples without evidence of infertility.8, 9 Fertility-focused intercourse approaches 
include tracking basal body temperatures (BBT), using luteinizing hormone (LH) test 
kits, monitoring cervical mucus (CM), and counting cycle days using a simple calendar 
method to predict fertile days. These approaches are intended to optimize natural fertility 
rather than treat an underlying condition. Monitoring menstrual cycles using the 
biosymptom approaches can be useful in determining underlying conditions contributing 
to a couples’ difficulty conceiving.10 However, it is critical for individuals attempting to 
conceive to use these methods correctly.11 There is potential to inadvertently practice 
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pregnancy prevention or to misinterpret observations if these methods are poorly 
understood.   
Other nonmedical interventions include loosing or gaining weight to achieve a 
“normal” or healthy body mass index (BMI) and to improve overall health and 
reproductive capacity. The American Society for Reproductive Medicine (ASRM) 
estimates that about 12% of infertility cases are due to the female partner weighing too 
little or too much.12 BMI that is too high (>25kg/m2) or too low (<19 kg/m2) can affect 
ovulation and cycle length.13  
Although different from weight management interventions, another behavioral 
change that is sometimes reported is the use of “fertility diets.”  Fertility diets typically 
recommend changing micronutrient profiles to enhance fertility. A growing body of 
research substantiates these interventions.14 Any Google search for “foods to enhance 
fertility,” or “fertility diets” will provide ample reading pointing to a mixture of 
pseudoscientific claims as well as claims based on scientific research on food and diet 
changes that can improve a couple’s chance of conceiving.  
Couples having difficulty conceiving may turn to a variety of interventions or 
treatments that are outside the realm of conventional medicine. These approaches are 
sometimes referred to as complementary and alternative medicines (CAM). Although 
there are a many CAM approaches that have been explored, some of the more commonly 
reported fertility-related interventions include the use of vitamins, herbs, and/or 
acupuncture.15, 16 
Vitamins are generally considered a more western approach to health than herbs 
or acupuncture, but use of vitamin supplements is often considered CAM, as they are not 
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routinely evaluated in clinical trials. Common vitamins that are used to enhance fertility 
include B-complex, vitamin C, vitamin E, and folic acid for women and L-carnitine, 
vitamin C, vitamin E, vitamin A, selenium, zinc, and beta-carotene for men. Studies yield 
mixed findings on the efficacy of vitamin supplements for the treatment of infertility or 
enhancement of fertility.17-20 
 The prevalence of use of medicinal herbs varies greatly between cultures and 
geographic regions of the world.  A recent 18-month prospective cohort study of infertile 
couples in the United States found that about 17% of couples report using herbs to 
enhance their fertility while undergoing ART.16 Herbs used in products that are marketed 
to enhance fertility include vitex, red clover, Siberian ginseng, ginko biloba, maca root, 
and Asian ginseng.21 There has been some research of varying quality on herbal 
supplements and their effect on fertility.22-24 
Acupuncture is a traditional Chinese medicine practice that involves placing 
needles in the skin to stimulate certain points on the body.25-30 Smith et al. (2010) found 
that 22% of infertile couples in their study used acupuncture over the course of 18 
months.16 The effects of acupuncture on infertility have been inconclusive. Some 
evidence suggests that acupuncture provided in conjuncture with embryo transfer may 
increase rates of pregnancy and live birth31; however, a Cochrane review found no 
evidence to support acupuncture and went further to recommend against acupunctures 
use with IVF during egg retrieval or implantation.25 A 2013 meta-analysis of randomized 
trials of acupuncture and IVF embryo transfer found no pooled benefit for providing 
acupuncture with IVF embryo transfer.27 
Modern technology, mommy blogs, and social media have provided couples 
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wishing to conceive with a plethora of unsubstantiated information on ways to enhance 
fertility. The purpose of this analysis is to describe the use of various behavioral, 
nonmedical and medical interventions among a cohort of women from the general 
population and specialty infertility clinics with a history of primary infertility. We also 
examine the use of combinations of interventions, including interventions utilized by 
male partners. Pregnancies that occurred during the cycles when these approaches were 




The Fertility Experiences Study (FES) is a retrospective cohort study conducted at 
the University of Utah between April 2010 and September 2012. The FES cohort was 
developed with the intention of identifying women with primary infertility that may or 
may not have received clinical diagnosis or medical treatment. Women were recruited 
from infertility clinics as well as the general population. The clinic-based cohort was 
recruited from two specialty fertility clinics in Utah. For clinic recruitment, study 
invitations were mailed to all women who had an initial infertility visit during the index 
years of 2004 and 2008.  The population-based cohort was identified by the Utah 
Population Database (UPDB) based on a linkage between state marriage, birth, and fetal 
death records.  Couples with a marriage record and no record of a live birth or fetal birth 
within 2 years of marriage were considered eligible for screening. Recruitment of the 
population-based cohort was facilitated by the Resource for Genetic and Epidemiologic 
Research (RGE) at the University of Utah to protect the identity of women who were not 
interested in enrolling. RGE mailed invitation letters and followed up potential 
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participants to inform them of the study and determine if they would be willing to be 
contacted by study staff for eligibility screening. Interested individuals from both the 
general population and two specialty clinics were screened for eligibility using the same 
criteria. The parallel clinic-based and population-based cohorts consist of women 
residing in the State of Utah with a history of primary infertility (i.e., trying to conceive 
for at least 1 year, with no prior pregnancies) as of a specified index date between 2004 
and 2008. Women determined to be eligible were then invited to complete a self-
administered online (or paper) questionnaire. Upon completion of the questionnaire, 
trained study staff completed an in depth phone interview. Participants received a $10 gift 
card and a handwritten thank you note as compensation for their time. The development 
of the FES cohort and data collection methodology has been described in detail elsewhere 
(Cite methods paper). The University of Utah Institutional Review Board approved this 
study. 
During the in-depth phone interview study staff read the line “I will now ask 
about things you may have done to enhance fertility during this particular attempt to 
conceive, either on recommendation of a doctor or on your own…. In order to conceive, 
have you done any of the following: [Intervention], during this particular attempt? If so 
was it used during the month of conception of pregnancy?”  
Descriptive analysis was performed to examine characteristics of women who 
utilized various interventions with the specified goal of increasing their fertility. We 
created treatment categories by combing interventions.  Fertility-focus intercourse 
includes BBT, urine LH tests, counting days, and monitoring CM; weight loss and the 
use of “fertility diets” were grouped as behavioral interventions; CAM measures included 
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vitamins, herbs, and acupuncture; and medical treatments included OS, IUI, and ART. 
Mutually exclusive categories of interventions (other than behavior changes and fertility-
focused intercourse) were created to identify the most invasive treatments/interventions 
used for women who used a variety of approaches. Women who used only fertility 
focused intercourse, fertility diets, or weight loss were categorized as using no 
treatments. Women who used vitamins, herbs, or acupuncture without medical treatments 
and with or without behavioral changes were categorized as using CAM. Medical 
treatments were grouped as follows: women who had used OS (without IUI or ART), 
women who used IUI (with or without OS and/or CAM/behavioral changes), and women 
who used ART (with or without any other interventions). A subset of participants was 
also asked about interventions that their male partners used during their pregnancy 
attempts and the prevalence of partner-focused interventions was documented. Chi-
square tests were used to evaluate differences in the frequency of use of each 
intervention, stratified by participant characteristics. Combinations of treatments ever 
used are also described. Multivariable logistic regression models were assessed to assess 
for characteristics that made women more likely to use a particular intervention. 
Covariates considered were recruitment cohort (clinic vs. population), age at start 
of first pregnancy attempt, education level, religious affiliation (specifically affiliation 
with the Church of Jesus Christ of Latter-Day Saints), income level, race/ethnicity, 
longest pregnancy attempt duration over 24 months, pregnancy outcomes, and other 







A total of 960 women enrolled in FES; 501 women were recruited from the 
population and 459 women were recruited from infertility clinics. Most women enrolled 
(92%) completed all three parts of the study including the screening questionnaire, the 
self-administered questionnaire, and the phone interview. Nineteen women with missing 
pregnancy attempt data were dropped from the analysis: four women had dates that were 
improperly formatted and 15 women had missing attempt end dates but were not “still 
trying to conceive” at the time of the interview. A total of 867 women were retained for 
the analysis. Half of the women were recruited from fertility clinics, and half were 
recruited from the general population.  Women recruited from the general population 
were younger on average and had lower incomes than infertility clinic patients. Less than 
half of the women were asked about insurance coverage for fertility but of women who 
were asked, 75% indicated they had some insurance coverage for diagnostics or treatment 
in both cohorts (p = 0.78). Women recruited from the clinic reported having longer 
pregnancy attempt duration and were more likely to use IUI or ART than women 
recruited from the population cohort (Table 3.1).  
Two thirds of women eventually had a pregnancy; approximately two-thirds  (n = 
541) had at least one pregnancy, 91% (n = 492) of these pregnancies resulted in a live 
birth, and 9% (n = 49) had at least one pregnancy but had never had a live birth (this 
includes 14 women who were currently pregnant at the time of the phone interview for 
whom pregnancy outcomes are unknown). Women recruited from the specialty clinics 
used different types of treatments than women recruited from the general population; 
however, there was no difference in the proportion of women achieving at least one 
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pregnancy in the two groups (64% versus 63%; p = 0.76). There were significantly more 
clinic recruited women who had at least one pregnancy ending in a multiple gestation 
birth compared to women recruited from the population (23% versus 11%; p-value < 
0.01).   
The most commonly used intervention was fertility-focused intercourse, which 
was reported by 94% of participants. Of women who had a pregnancy, 60% indicated 
they were using some fertility-focused method during the cycle of conception. Other 
behavioral interventions asked about were weight loss and the use of fertility diets, and 
35% of women reported that they had ever used these behavioral interventions to enhance 
their fertility, whereas 9% were using these methods during the month of conception. 
Complementary and alternative interventions were reported by a third (33%) of women 
(Table 3.2). Of women who were using CAM, 20% of vitamin users were using them 
during the month of conception, 11% of herb users were using the herbs during the month 
of conception, and 9% of acupuncture users were using it during the month of 
conception.  
Medical treatment was common in both clinic and population cohort recruited 
women. Eight out of 10 women in the study reported using OS as some point in their 
attempt history, and 35% of women whom ultimately had a pregnancy in the study 
conceived during an OS cycle. Half of the women reported using IUI during their 
pregnancy attempts and 35% conceived in an IUI cycle. ART was the least frequently 
reported medical intervention reported, but about 38% of women who had pregnancies 
achieved them during an ART cycles (Figure 3.1).  
During the pregnancy attempt history, women frequently reported using more 
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than one method to enhance their fertility (Table 3.3). Only 3% of women reported not 
using anything during their pregnancy attempt history (fertility focused intercourse, 
weight loss, fertility diets, vitamins, herbs, acupuncture, OS, IUI, ART).  The average 
number of interventions used was 3.4, but ranged from 0 to 8 (potential max is 9). 
Overlap in interventions may indicate sequential or concurrent use. Nearly all (99%) 
individuals who had used any intervention, CAM, OS, IUI, or ART, also used a fertility-
focused intercourse approach, whereas only 78% of women who never used any 
intervention were using any of these methods.  
Use of fertility diets were not as common as other interventions in this cohort; 
only 16% indicated they had ever used a fertility diet. Weight loss was commonly 
reported among all women (29%). Women who were overweight or obese at the time of 
the interview more frequently (42%) reported weight loss as something they had ever 
tried. Individuals who had less than college education also more frequently reported 
weight loss as an intervention used. Women with no insurance coverage for treatment or 
diagnosis less frequently reported using fertility diets. Women who used CAM as their 
highest treatment more frequently reported using fertility diets followed by women who 
had used ART.  Women who had used OS were the most likely to report weight loss out 
of the mutually exclusive treatment categories. There was a distinction made between 
fertility diets and weigh loss. Only about 10% of women reported using both “fertility 
diets” and weight loss during their pregnancy attempt histories.  
   A third of women (n = 287) reported using CAM in at least one attempt, but 
only 4% (n = 31) reported CAM as their most invasive treatment. When combining all 
CAM, women who had no insurance coverage for any fertility treatment or diagnosis 
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reported less use of CAM. However, there were other differences between characteristics 
when looking at vitamins, herbs, and acupuncture separately. More frequent use of 
vitamins were reported by women who were underweight or normal BMI compared to 
overweight or obese women, those who had incomes over $100,000 compared to women 
who reported lower incomes, and those who never had a pregnancy. Individuals from the 
clinic-based cohort compared to the population-based cohort and those who had never 
had a pregnancy more frequently reported use of herbs. Acupuncture was more 
frequently used by women who were 31 years of age or older than younger women, 
women who were underweight, or normal BMIs at the time of the interview.  
There was a high rate of medical treatment used in this population, with 81% (n = 
703) reporting some type of medical treatment during their attempt to conceive. Close to 
three quarters of the women in FES reported the use of ovulation enhancing drugs during 
at least one attempt (n = 629). Over two-thirds of these women also had more invasive 
treatments. Four-hundred and thirty-six women (50%) used IUI during at least one 
attempt; close to half of these women who used IUI also used IVF (n = 317). There were 
significantly more women reporting all three treatments among those recruited from the 
clinics. Both IUI and ART treatments were most frequently reported by women who were 
underweight/normal BMI, had annual incomes over $100,000, and had some insurance 
coverage for infertility diagnosis or treatment. ART was also most frequently reported by 
women who were over 31 years of age at the beginning of their first attempt. Of women 
who used some medical treatment, only 28% of individuals use a single medical 
intervention. Many women (14%) reported using ovulation enhancing drugs, IUI, and 
ART consecutively during a single pregnancy attempt, though not during the same cycle.  
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Overall, only 15% (n = 133) of women in this cohort did not use any medical 
interventions to enhance their fertility, this may have been indicative of less severe 
fertility as these women has significantly shorter pregnancy attempt duration (50% less 
than 24-months) compared to women who used treatment and had similar rates of 
pregnancy (60%). 
A subgroup of 363 women were asked specifically about things their male 
partners may have done to enhance fertility during attempts to conceive. The most 
common intervention used by male partners was weight loss (6%). Women reported that 
male partners also used fertility diets (5%), vitamins (6%), herbs (5%), acupuncture (2%), 
medications such as Clomid (3%), and hormonal treatments (3%). Women who were 
overweight or obese also more frequently reported male partner weight loss.  About 5% 
of women who were asked reported that both they and their partner had lost weight to try 
to enhance their fertility, while 4% reported both partners had used “fertility diets.” Only 
three (<1%) women reported that they and their partner used both fertility diets and 
weight loss as a way to enhance their fertility (Table 3.4). 
When adjusting for recruitment cohort, age at first attempt, BMI category, 
income, education, ethnicity, pregnancy, and longest attempt duration, women who self 
identify as LDS were 2.1 times as likely to practice fertility focused intercourse than non-
LDS women. Women who used CAM were 4.43 times as likely [95% CI 1.27-15.41] as 
women who did not used any CAM to incorporate fertility-focused intercourse into their 
attempts. Women who ever used OS or IUI were also more likely to report fertility- 
focused intercourse [aOR 3.2; 95% CI 1.46-7.06] and [aOR 7.46; 95% CI 1.61-34.66], 
respectively. Multivariable regression controlling for the same aforementioned 
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confounders found LDS women less likely than non-LDS women to use CAM [aOR 
0.64; 95% CI 0.42-0.98]. Women who reported ever using fertility focused intercourse 
were 4.5 times more likely than nonusers to report CAM interventions. IUI users were 
1.5 times more likely than non-IUI users, and ART users were 2.5 times more likely than 
non-ART users to report ever using CAM (Table 3.5). When collapsing all medical 
treatment into a single category (medical treatment vs. no medical treatment) women 
from the clinic-based cohort were 9.4 times more likely to report ever using a medical 
treatment, LDS women were 2 times more likely to use medical treatments than non-LDS 
women, and women who had attempts lasting longer than 24 months were also more 
likely to use any medical treatment compared to women who had shorter attempts, when 
controlling for age, BMI, income, education, and ethnicity (Table 3.6). 
Separate multivariable logistic regression was done to assess the association of 
interventions with each other (Table 3.7). When controlling for recruitment site, age, 
BMI, income, education, race/ethnicity, and religion, women who used medical 
interventions were 5.2 times as likely to use fertility focused intercourse than women who 
did not use any medical treatments. They were also 1.94 times as likely to use some type 
of CAM during their pregnancy attempts. Women who had longest attempts of longer 
than 24 months were about twice as likely to use CAM and/or medical treatments than 





In this study, nearly all participants (94%) engaged in fertility-focused intercourse 
methods during at least one pregnancy attempt. A third of women (35%) either lost 
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weight or changed their diet with the intention of enhancing their fertility. A third of 
women (n = 287) also reported using CAM in at least one attempt but only 4% (n = 31) 
reported CAM as their most invasive treatment. There was a high rate of medical 
treatment used in this population, with 81% (n = 703) reporting some type of medical 
treatment, including OS, IUI, and/or ART.  Overall, only 15% (n = 133) of women in this 
cohort never used any intervention to enhance their fertility.  In the subgroup of women 
who were asked about things their partner might have done to enhance fertility there were 
few that reported any male partner interventions, suggesting that men are not as engaged 
in behavioral modifications or self-care interventions as their female counterparts. Given 
that in 40% of infertile couples, the underlying cause of infertility involves some male 
factor, this is an area of research that should be explored further as there may be potential 
to increase a couples natural fertility by involving men in healthy behavioral 
modifications that may benefit sperm quality or motility.32 A major limitation of the 
study is that the dates of interventions were not collected; thus, we are unable to account 
for order of interventions used, exact duration of intervention use, or concurrent use of 
interventions if participants indicated their use during a single pregnancy attempt.  We 
were only able to identify concurrent use of interventions if they were used in a cycle 
resulting in a conception.   
  The design of the FES is unique in that it explores interventions by couples with a 
history of primary infertility recruited through fertility clinics as well as women who 
were recruited through a population-based sample. This allows us to examine how 
women may attempt to enhance their fertility outside of fertility clinics. The use of 
nonmedical interventions was common in both the clinic and population recruited cohort. 
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It is necessary for providers to complete a full intervention inventory in addition to 
medical history with patients at all clinical encounters. Having a more complete picture 
of the things that women are doing either on their own or with CAM practitioners or 
other medical providers can improve treatment precision. Providers need to acknowledge 
that more likely than not their patients are engaging in nonmedical interventions with the 
intention of enhancing their fertility, but without adequate counseling women may be 
using approaches that could have opposing effects on treatments. Women who have been 
trying for longer are also more likely to engage in more interventions and should be 
asked to report on the things they may have tried over the years. The use of an 
intervention checklist to assess what nonmedical interventions patients are using has the 
potential to create open communication between patients and specialty providers by 
removing stigma surrounding nonmedical CAM and ensuring that providers have the 
most complete clinical picture when treating individual cases. This may also be an 
opportunity to ensure that their long durations of “regular, unprotected intercourse” also 
included at least 12 cycles of appropriate fertility-focus intercourse. These interactions 
with patients who are struggling to conceive is an ideal opportunity to discuss 








Table 3.1 Demographic and reproductive characteristics of participants by source cohort 
(N = 867) 
 
  Clinic Population Total P-value 
 N % N % N %  
Total 433 49.9% 434 50.1% 867 100.0%  
Age at first attempt to conceive        
≤25 206 56.9% 317 73.2% 523 65.8% 0.000 
26-30 110 30.4% 107 24.7% 217 27.3%   
31+ 46 12.7% 9 2.1% 55 6.9%   
BMI Category               
Underweight 7 1.8% 14 3.5% 21 2.6% 0.238 
Normal 200 50.4% 179 45.1% 379 47.7%   
Overweight 95 23.9% 107 27.0% 202 25.4%   
Obese 95 23.9% 97 24.4% 192 24.2%   
Annual Income               
Less than $50,000 105 25.4% 157 37.6% 262 31.5% 0.000 
50,000-$99,999 232 56.2% 226 54.1% 458 55.1%   
Over $100,000 76 18.4% 35 8.4% 111 13.4%   
Education Level               
Less than college graduate 152 35.3% 158 36.4% 310 35.8% 0.727 
College graduate or more 279 64.7% 276 63.6% 555 64.2%   
Race/Ethnicity               
White, Non-Hispanic 402 92.8% 413 95.2% 815 94.0% 0.150 
Hispanic or other non-white 31 7.2% 21 4.8% 52 6.0%   
Religion               
Non-LDS 114 26.3% 91 21.0% 205 23.6% 0.063 
Latter-Day Saint 319 73.7% 343 79.0% 662 76.4%   
Insurance coverage for fertility               
None or unsure 32 7.4% 59 13.6% 91 10.5% 0.000 
Some coverage 100 23.1% 172 39.6% 272 31.4%   
Not asked 301 69.5% 203 46.8% 504 58.1%   
Longest attempt duration               
<12mo 6 1.4% 36 8.3% 42 4.8% 0.000 
12-<24 68 15.7% 89 20.5% 157 18.1%   
24-<36 80 18.5% 85 19.6% 165 19.0%   
36-<48 78 18.0% 59 13.6% 137 15.8%   
48+ 201 46.4% 165 38.0% 366 42.2%   
Fertility Outcome               
No Pregnancy 160 37.0% 166 38.3% 326 37.6% 0.496 
Pregnancy, live birth 252 58.2% 240 55.3% 492 56.8%   







Table 3.2 Fertility interventions used by participants’ demographic and reproductive outcome




Behavioral Changes Complementary-Alternative Medicine Medical Treatment 
  Total  Any  Fertility Diet Weight Loss Vitamins Herbs 
Acupunctur
e OS IUI ART 
Total N (%) 867 94.3% 16.4% 28.6% 12.0% 17.1% 15.6% 72.5% 50.3% 36.6% 
Recruitment Site 867                   
Clinic 433 91.7%** 15.2% 27.3% 11.5% 20.1%* 16.6% 77.1%* 61.2%* 47.8%* 
Population 434 82.9%** 15.9% 27.0% 12.4% 14.1%* 14.5% 58.5%* 33.6%* 21.0%* 
Age at 1st attempt 795                   
≤25 523 93.6% 17.9% 30.3% 12.4% 17.3% 14.5%* 71.1% 45.7% 32.7%* 
26-30 217 92.6% 12.9% 24.4% 11.1% 14.3% 17.1%* 72.4% 52.1% 35.0%* 
31+ 55 92.7% 18.2% 18.2% 12.7% 16.4% 23.6%* 69.1% 54.5% 63.6%* 
BMI Category 794                   
Underweight/Normal 400 94.3% 15.3% 14.8%** 14.8%* 16.0% 17.8%* 71.8% 54.8%* 42.5%* 
Overweight/ Obese 394 93.7% 17.3% 42.6%** 9.6%* 17.3% 12.4%* 74.6% 46.2%* 32.5%* 
Annual Income 831                   
Less than $50,000 262 92.4% 15.6% 32.8% 12.6%* 17.9% 13.0% 67.6% 40.1%* 28.2%* 
50,000-$99,999 458 90.1% 14.4% 25.2% 9.9%* 16.5% 15.1% 71.3% 50.9%* 33.6%* 
Over $100,000 111 93.7% 21.6% 27.9% 18.9%* 14.4% 18.0% 73.0% 61.3%* 59.5%* 
Education Level 865                   
Less than college grad 310 92.9% 17.1% 32.6%* 11.6% 18.7% 14.8% 73.2% 48.7% 32.9% 
College grad or more 555 95.1% 16.0% 26.5%* 12.3% 16.2% 16.0% 72.3% 51.4% 38.4% 
Race/Ethnicity 867                   
White, Non-Hispanic 815 94.6% 16.3% 28.6% 11.9% 16.8% 15.2% 72.9% 50.3% 36.8% 
Hispanic, Other Non-
White 52 90.4% 17.3% 28.8% 13.5% 21.2% 21.2% 67.3% 50.0% 32.7% 
Religion 867                   
Non-LDS 205 91.7% 17.6% 29.3% 14.1% 17.6% 18.5% 69.3% 47.8% 35.6% 
Latter-Day Saint 662 95.2% 16.0% 28.4% 11.3% 16.9% 14.7% 73.6% 51.1% 36.9% 
Insurance coverage 
for fertility 867                   
None or unsure 91 85.7%* 9.9%* 14.3% 11.0% 24.2% 47.3%* 28.6%* 33.0%* 23.1%* 
Some coverage  272 95.2%* 12.9%* 25.0% 9.2% 23.9% 69.1%* 47.1%* 37.1%* 26.5%* 
Not asked 504 95.4%* 19.4%* 33.1% 19.8% 39.7% 79.0%* 30.6%* 60.5%* 44.4%* 
Longest attempt 
duration 867                   
<24 months 199 90%** 14.1% 26.1% 6.5%** 7.0%** 15.6% 60.8%** 31.2%** 23.6%** 









































Table 3.3 Overlap between fertility interventions ever used 
































































BBT 100% 81% 65% 92% 31% 20% 15% 21% 19% 81% 57% 40% 
LH-Test 65% 100% 57% 93% 28% 16% 13% 20% 16% 80% 59% 37% 
Monitoring 
CM 70% 83% 
100
% 93% 33% 25% 15% 22% 24% 76% 58% 43% 
Counting 
days 65% 82% 60% 
100
% 29% 17% 13% 19% 17% 76% 53% 37% 
Weight Loss 65% 74% 65% 88% 100% 37% 16% 19% 30% 83% 57% 42% 
Fertility Diet 74% 74% 86% 89% 64% 100% 20% 23% 56% 86% 68% 61% 
Vitamins 76% 82% 70% 90% 38% 28% 100% 50% 24% 79% 55% 42% 
Herbs 74% 86% 70% 95% 32% 22% 35% 100% 26% 82% 58% 36% 
Acupuncture 74% 77% 85% 92% 55% 59% 19% 28% 100% 92% 79% 70% 
OS 67% 83% 58% 90% 33% 19% 13% 19% 20% 100% 65% 41% 
IUI 68% 88% 63% 90% 33% 22% 13% 20% 24% 93% 100% 52% 
ART 67% 76% 64% 87% 32% 27% 14% 17% 30% 81% 71% 100% 
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  Unadjusted OR [95% CI] Adjusted OR [95% CI] 
Recruitment Site     
Population Reference Reference 
Clinic 1.22 [ 0.92-1.62] 0.7 [0.48-1.02] 
Age at 1st attempt     
<25 Reference Reference 
>=25 0.95 [0.70-1.28] 0.91 [0.63-1.32] 
BMI Category     
Underweight/Normal Reference Reference 
Overweight/ Obese 0.82 [0.61-1.11] 0.86 [0.6-1.21] 
Annual Income     
Less than $50,000 Reference Reference 
50,000-$99,999 0.92 [0.67-1.27] 0.71 [0.48-1.06] 
Over $100,000 1.05 [0.66-1.68] 0.8 [0.44-1.45] 
Education Level     
Less than college grad Reference Reference 
College grad or more 0.95 [0.70-1.28] 1.03 [0.71-1.49] 
Race/Ethnicity     
White, Non-Hispanic Reference Reference 
Hispanic, Other Non-White 1.18 [0.66-2.11] 1.25[0.6-2.6] 
Religion     
Non-LDS Reference Reference 
Latter-Day Saint 0.86 [0.62-1.20] 0.64 [0.42-0.98] 
Pregnancy      
No pregnancy Reference Reference 
Pregnancy  0.81 [0.60-1.09] 0.71 [0.49-1.02] 
Longest Attempt Duration      
<24 months Reference Reference 
24 months or longer 2.01 [1.39-2.92] 1.41 [0.9-2.22] 
Other Treatments/Interventions ever 
used     
Fertility Focused Intercourse* 8.15 [2.5-26.45] 4.47 [1.31-15.2] 
Drugs* 2.59 [1.81-3.71] 1.5 [0.95-2.38] 
AI* 2.60 [1.93-2.49] 1.57 [1.05-2.36] 
ART* 2.48 [1.84-3.32] 2.52 [1.72-3.69] 
*Reference is never using these interventions 
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Model 1. Adjusted OR 
[95% CI] 
Model 2. Adjusted 
OR [95% CI] 
Recruitment Site       
Population Reference Reference Reference 
Clinic 7.69 [4.90-12.08] 9.36 [5.23-16.77] 9.12 [5.09-16.35] 
Age at 1st attempt       
<25 Reference Reference Reference 
≥25 1.17 [0.82-1.66] 1.02 [0.65-1.6] 1.03 [0.65-1.61] 
BMI Category       
Underweight/Normal Reference Reference Reference 
Overweight/ Obese 1.18 [0.82-1.69] 1.45 [0.95-2.2] 1.38 [0.9-2.11] 
Annual Income       
Less than $50,000 Reference Reference Reference 
50,000-$99,999 1.66 [1.15-2.42] 1.34 [0.85-2.1] 1.27 [0.80-2.00] 
Over $100,000 2.15 [1.17-3.97] 1.75 [0.8-3.81] 1.82 [0.82-4.07] 
Education Level       
Less than college 
grad Reference Reference Reference 
College grad or more 1.11 [0.78-1.58] 1.15 [0.73-1.79] 1.09 [0.69-1.71] 
Race/Ethnicity       
White, Non-Hispanic Reference Reference Reference 
Hispanic, Other Non-
White 0.76 [0.39-1.49] 0.6 [0.25-1.43] 0.66 [0.27-1.58] 
Religion       
Non-LDS Reference Reference Reference 
Latter-Day Saint 1.43 [0.98-2.10] 2.05 [1.25-3.34] 1.93 [1.17-3.17] 
Pregnancy        
No pregnancy Reference   Reference 
Pregnancy  1.43 [1.01-2.04]   1.69 [1.08-2.66] 
Longest Attempt 
Duration        
<24 months Reference Reference Reference 








Table 3.7 Association between different types of intervention, adjusted for demographic 






















Duration   
  
<24 months Reference Reference Reference Reference 
24 months or longer 
1.32[0.62-
2.82] 




























1.26 [0.76-2.12] 1.94 [1.15-
3.28] 
NA 
*Reference is never using this intervention 
 
*Each column is a separate logistic regression model, and in addition to the variables shown is 
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FERTILITY TREATMENTS AND THE RISK OF PRETERM BIRTH AMONG 





The objective of this aim is to determine the effect of fertility treatment (in vitro 
fertilization (IVF), intrauterine insemination (IUI), usually with ovulation drugs (IUI), or 
ovulation drugs alone) on preterm birth, compared to no treatment in subfertile women. 
To achieve this aim we used parallel retrospective population and clinic cohorts linked to 
birth certificate data. Women with a history of primary subfertility were linked to first 
birth or fetal death record within the state of Utah (N = 491).  Self-reported fertility 
treatments, diagnoses, and duration of subfertility were obtained from online and 
telephone questionnaires. Participants were linked to birth certificates and fetal death 
records for data on perinatal outcomes.  
A total 487 birth certificates and three fetal death records were linked as first 
births for study participants who completed questionnaires.  Among linked births, 19% 
were PTB. After adjustment for maternal age, paternal age, maternal education, annual 
income, religious affiliation, female or male fertility diagnosis, and duration of 
subfertility, the odds ratios and 95% confidence intervals (CI) for PTB were 2.2 (95% CI 




conceived using IUI, and 4.2 (95% CI 2.1-8.8) for neonates conceived by IVF, compared 
to women with subfertility who used no treatment during the month of conception. A 
reported diagnosis of female factor infertility increased the adjusted odds of having a 
PTB 3.0 (95% CI 1.5-6.0). Duration of pregnancy attempt was not independently 
associated with PTB. In restricting analyses to singleton gestation, odds ratios remained 
elevated but were not significant for any type of treatment. 
IVF, IUI, and ovulation drugs were all associated with a higher incidence of 
preterm birth and low birth weight, predominantly related to multiple gestation births. 
The findings support changes to treatment protocols to maximize singleton gestation and 





Approximately one in every seven couples experiences difficulty conceiving or 
maintaining a pregnancy; this prolonged duration of nonconception is referred to as 
subfertility.1-4 Subfertility is commonly identified as a clinical “infertility” when a couple 
desiring conception has had regular unprotected intercourse for 12 months or longer 
without achieving pregnancy.1 There are varying degrees of subfertility and a variety of 
potential underlying causes: abnormalities in oocyte production, abnormalities in sperm 
production, abnormalities in reproductive tract transport of the sperm, oocyte, and/or 
embryo, abnormalities in the implantation process, or other conditions that affect one or 
multiple components of the reproductive process.5 Diagnostic tests and tracking 
menstrual cycle patterns can help to determine the underlying etiology of the 
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unsuccessful pregnancy attempts.6 However, frequently providers are unable to identify 
the precise cause of a couple’s subfertility and in 15-30% of cases assign more 
ambiguous diagnosis of unexplained infertility.7   
About half of subfertile couples seek medical treatment.8 Common medical 
approaches to overcoming subfertility include the use of in vitro fertilization (IVF), 
intrauterine insemination (IUI), and ovulation stimulation (OS). In the past 3 decades, the 
focus of fertility research and treatment has increasingly shifted from less invasive 
medical treatments (including OS and IUI) to more invasive, specifically IVF.  IVF was 
originally developed to overcome absolute subfertility due to blockage or absence of the 
fallopian tubes and later expanded to treat severe male subfertility with the addition of 
intracytoplasmic sperm injection (ICSI) (i.e., specific indications for IVF), but is now 
frequently used for couples with diminished fertility due to any cause as well as those 
with infertility of unknown cause.9, 10 While some advocate that IVF should become a 
primary management strategy for couples without specific indications because of its high 
probability of success per cycle success, there are substantial concerns about expanding 
use of IVF, including high cost and impact on neonatal outcomes.9, 10 Epidemiologic 
studies have demonstrated higher incidence of preterm birth (PTB), low birthweight 
(LBW), and birth defects among children conceived through IVF, when compared to 
children conceived naturally, even when the analyses are limited to singleton 
pregnancies.11-13  
In the United States, the Society of Assisted Reproductive Technology (SART) 
and the Center for Disease Control conduct fertility clinic level surveillance with the goal 
of tracking IVF procedures and outcomes.14, 15 The proportion of live births conceived 
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through IVF average 1.4% but vary by region (range: 0.2% in Puerto Rico to 4.3% in 
Massachusetts)16; however, across the nation IVF births contribute to a considerable 
proportion of the PTB and LBW infants born each year.  No formal surveillance exists 
for the less invasive treatments, but exposure to these fertility treatments (OS and IUI) 
may also be associated with adverse perinatal outcomes.17-19 It is estimated that OS 
accounts for up to 6% of the births in the United States and about 1% of births results 
from IUI.17, 20 However, monitoring birth outcomes and assessing risks associated with 
each of these medical exposures are critical public health concerns.  Additional questions 
remain as to whether these adverse outcomes are related to the treatments or to the 
underlying causes or severity of the subfertility.11, 21 Few studies exist that assess the 
independent risks of subfertility.12  
This research aims to provide insight into the relationship between fertility 
treatments (OS, IUI, and IVF) and preterm birth among women with primary subfertility 
compared to subfertile women who conceived without fertility treatment. We used data 
from parallel clinic and population-based cohorts, and examined the contribution of 
pregnancy attempt duration and fertility-related diagnoses, as well as the role of multiple 
gestations.   
 
4.3 Methods 
4.3.1 Study Population and Data 
  The Fertility Experiences Study (FES) is a retrospective cohort study conducted at 
the University of Utah between April 2010 and September 2012. Two parallel cohorts 
were recruited. For the clinic-based cohort, participants were recruited from female 
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patients seen for a new consultation for subfertility and/or treatment at one of two 
specialty fertility clinics in Utah between 2000 and 2009. For the population-based 
cohort, two period based cohorts were recruited using the Utah Population Database 
(UPDB) to identify and recruit potentially eligible women of reproductive age range who 
were married as of 2002 or 2006 but had not yet had a live birth as of the end of 2004 or 
2008 (index dates).22 For both clinic and population-based cohorts, the final eligibility 
criteria were as follows: between 20-35 years of age at the index date, no pregnancies 
prior to index date, at least one year of regular intercourse without contraception with a 
male partner at the index date, and a Utah resident during three years following the index 
date. All participants in the study completed the Fertility Experiences Questionnaires 
(FEQ), which included a self-administered online questionnaire followed by a structured 
telephone interview with trained study staff.  In preparatory research in comparison to 
medical records, the FEQ was over 90% sensitive for pregnancy attempt duration, 
pregnancy outcomes, and use of IVF and IUI and 70% sensitive for the use of ovulation 
drugs (Thomas et al 
, in review). Data from 2000 to 2010 Utah birth and fetal death certificates were linked 
with data from women who completed both the online questionnaire and the structured 
telephone interview. The University of Utah Institutional Review Board approved this 
study.  
 
4.3.2 Classification of Exposure Status 
   The key exposure measure is the type of fertility treatment received during the 
month of conception that resulted in the first live birth or fetal death. Treatment groups 
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are defined based on the most invasive medical treatment used during the cycle of 
conception.  For the purposes of this study, the most invasive treatment is IVF. IVF 
includes all procedures that involve manipulating both sperm and eggs outside the body. 
The next most invasive treatment was considered to be IUI. Women were categorized as 
using IUI during the cycle of conception, regardless of if they were also using OS. If 
women only reported medication to stimulate or enhance ovulation during the conception 
cycle, then they were classified as using OS. Women who did not receive any medication 
or procedure during the cycle of conception were classified as having no treatment, even 
if they receive medical treatment during previous cycles or reported alternative 
nonmedical treatment (such as acupuncture or herbs). This group of untreated subfertile 
women was used as the control for the analysis.  
  We assessed the duration of pregnancy attempt duration, which provides an 
indicator of severity of subfertility. During the structured telephone interview, trained 
study staff asked each woman about specific dates when she was at risk for pregnancy. 
Pregnancy attempt duration was calculated as the interval between the date that the 
attempt began and the estimated date of conception. The estimated date of conception 
was calculated using birth certificate data for clinical gestational age at birth and date of 
birth.  
   Fertility-related diagnoses were obtained through the self-administered online 
questionnaire.  The question asked “have you or your partner ever been told or suspect 
that you have any of the following diagnosis?” Answers were yes, no, and unsure. 
Women who answered no or they were unsure were considered to have a negative 
answer. For this analysis, diagnoses were grouped into the Society for Assisted 
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Reproductive Technology Clinical Outcomes Reporting System (SARTCORS) 
categories.  SARTCORS categories are tubal factor, endometriosis, ovulation 
dysfunction, uterine factor, male factor, or unexplained. If women have more than one 
female factor diagnosed, then they are categorized as multiple female factors. If a couple 
has a female contributor and a male factor issue, then they are categorized as combined 
male and female factor. For this analysis, any female factor infertility was collapsed into 
a dichotomous variable, and any male factor was considered a separate dichotomous 
variable. 
 
4.3.3 Outcome Definition 
  The primary outcome measure was preterm birth. PTB is defined as any 
pregnancy that ended in a live birth or fetal death at less than 37 completed weeks of 
gestation as reported on the state birth certificate.23 Birth certificate gestational age is 
typically calculated by the hospital using last menstrual period, confirmed by first 
trimester ultrasound.  The occurrence of multiple gestations was also obtained from the 
birth certificate or fetal death certificate. In the state of Utah fetal death certificates are 
issued for in-utero demise after 20 weeks gestation.   
 
4.3.4 Covariates 
  Covariates for the analysis were based on known risk factors for fertility 
treatments and for preterm birth. Variables considered in the analysis include age of 
mother at delivery, age of male partner, maternal education, prepregnancy BMI, annual 
income, and religious affiliation.  Religious affiliation with the Church of Jesus Christ of 
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Latter-day Saints (LDS) was identified because of its strong association with avoiding 
behavioral risk factors such as tobacco use, alcohol use, and drug use.24 Parental age and 
maternal BMI were obtained from the birth certificate. Parental age was categorized as 
less than 30 years or 30 years old or older at the time of delivery. BMI was calculated 
using prepregnancy weight and height and dichotomized as underweight/normal BMI 
(<25kg/m2) and overweight/obese BMI (≥25kg/m2). Education, income, and LDS 
religious affiliation were obtained from the FEQ. Education was dichotomized as less 
than college graduation and college graduation or more. Income was grouped as annual 
household income of less than $50,000, $50,000-$99,000, and $100,000.  
 
4.3.5 Statistical Analysis 
  The frequency of PTB was compared across participant characteristics and 
exposure variables. Crude and adjusted odds ratios and 95% confidence intervals for each 
individual outcome were estimated using simple and multivariable logistic regression. 
Parental age, prepreganancy BMI, education, income, LDS religious affiliation, and 
treatment received during the cycle of conception were included in the base model.   
Subsequent models assessed exposures including extended duration of pregnancy attempt 
(less than 24 months versus 24 months or more), self-reported diagnosis categories 
(female and male factor categories), and multiple gestation dichotomized. We repeated 







4.3.6 Sensitivity Analysis 
  In sensitivity analysis, age, BMI, and duration of attempt were also analyzed as 
continuous variables. We performed an analysis, removing participants who reported 
fertility related diagnosis related to tubal factors, as these women would not have been 
able to conceive without treatment by IVF.  Additional sensitivity analysis was conducted 
for women who were subfertile using the screening question but may have had 
intervening breaks in their pregnancy attempt (due to birth control for personal or 
medical use, miscarriage, or other reasons) so that their discrete attempt leading up to 





Study participants reported a total of 492 first births in the FEQ telephone 
interview.  Of these, 491 were linked to state vital records—488 came from birth 
certificates and three came from fetal death records (Figure 4.1). Of the live births, 18.8% 
were preterm. Table 4.1 displays the distribution of maternal characteristics and 
demographics by PTB outcomes.  
In this cohort of women achieving a live birth, 41% reported having unexplained 
infertility, 40% reported male factor infertility, 54% reported a diagnosis of ovulation 
dysfunction, 27% endometriosis, 16% a tubal factor, 13% uterine faction infertility, 29% 
multiple female factors, 12% blocked or damaged fallopian tubes, and 27% male factor 
subfertility (not mutually exclusive). Types of treatments used during the cycle of 
conception did not vary significantly for women who reported tubal factor, 
endometriosis, or unexplained infertility. However, women who reported ovulatory 
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dysfunction more often reported OS medication during the conception cycle compared to 
other treatments, women with uterine factor most frequently reported IVF, and women 
with unexplained infertility most commonly reported not using any treatment during the 
cycle of conception (Table 4.2). Women who suspected or were told by a provider they 
had tubal factor infertility had a higher incidence of PTB than women without tubal 
factor (27% versus 17%; p-value < 0.05).  Women with multiple female factor diagnosis 
were also found to have more PTB than women without multiple female factors (25% 
versus 17%; p-value < 0.05). Women with endometriosis had a nearly significant higher 
incidence of PTB compared to women without endometriosis (24% versus 17%; p-value 
= 0.053) (Table 4.3). 
About 44% of the subfertile women conceived while not using any medical 
treatment during the cycle of conception, whereas 16% reported use of ovulation-
enhancing drugs, 13% used IUI, and 28% conceived using IVF.  Many women reported 
use of more invasive treatments outside the cycle of conception. For example, of women 
who conceived using no treatment, 15% reported unsuccessfully using OS previously, 
16% had tried IUI, and 16% had tried IVF (Table 4.4).  
In the unadjusted logistic regression analysis, the risk of preterm birth was 2 times 
higher (95% CI 1.3-3.4) for women recruited from the specialty subfertility clinics than 
women from the general population. All types of treatment used during the cycle of 
conception were also associated with increased odds of PTB in the unadjusted model 
when compared to women that conceived spontaneously. Multiple gestation birth was 22 
times as likely to occur at less than 37 weeks gestation (95% CI 12.3-39.8) in the 
unadjusted model.  
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After adjustment for maternal age, paternal age, maternal education, annual 
income, religious affiliation, female or male fertility diagnosis, and duration of 
subfertility, the odds of having a PTB were 2.2 times higher (95% CI 1.0-4.8) for women 
who conceived using ovulation drugs, 3.2 times higher (95% CI 1.4-7.2) for women who 
conceived using IUI and 4.2 time higher (95% CI 2.1-8.8) for women who conceived by 
IVF, compared to women with subfertility who used no treatment during the month of 
conception. Duration of pregnancy attempt was not independently associated with PTB. 
A reported diagnosis of female factor infertility increased the adjusted odds of having a 
PTB was 3.0 times higher (95% CI 1.5-6.0) compared to women who did not report any 
female factor infertility.  Although slightly attenuated when excluding women with tubal 
factor, the odds of PTB were still significant (aOR 2.75; 95% CI 1.42-5.31) for women 
with any female factor infertility. Only 6.6% of the births conceived without any 
treatment during the month of conception were twins, for OS this increased to 19% twins 
and 6% triplets, IUI births were 10.9% twins and 5% triplets, and IVF births were 30% 
twins and 2% triplets.  Multiple gestations had the highest association with adverse 
neonatal outcomes (aOR 28.0; 95% CI 15.6-68.6) when controlling for all other variables. 
In restricting analyses to singleton gestation, odds ratios remained elevated but were no 
longer significant for any type of treatment (Table 4.5). However, female factor infertility 
was found to be independently associated with PTB when controlling for treatment, 











  When compared to subfertile women who did not use any fertility treatments 
during the cycle of conception, women who used any kind of fertility treatment were 
more significantly more likely to deliver preterm. As the invasiveness of treatment 
increased, so did both the incidence of multiple gestations and the incidence of PTB.  
Women who used OS to conceive were more than 2.5 times as likely to deliver preterm 
compared to women who used no treatment. Women who conceive using IUI and IVF 
are about 3.5 times as likely to experience a PTB as the subfertile women who do not use 
any treatment. Multiple gestations had the highest association with PTB. An independent 
association between female factor infertility etiology and PTB was also uncovered even 
when controlling for multiple gestations. This study may have been underpowered to 
examine the impact of specific diagnosis on PTB risk (i.e, endometriosis and tubal 
infertility) and of the impact of fertility treatment on PTB in singleton births.  Other 
recent population-based research has indicated an association of IVF with PTB among 
singletons.12   
   These findings are consistent with previous literature that used birth registries to 
look at non-IVF births among women who were subfertile.21 Our findings are consistent 
with findings from Danish national registries that saw a marked increased in PTB in 
births conceived through IUI.25 Research examined “low-technology” treatment and 
determined an increased risk of PTB as well as a history of research that has seen an 
increase risk of PTB among births conceived through IVF.11, 18, 25, 26 Few studies have 
compared birth outcomes of subfertile women conceiving with fertility treatments with 
subfertile women who conceive spontaneously.12 The use of an untreated subfertile 
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population as the referent category for a variety of treatment exposures is a strength of 
this study and may present a treatment effect magnitude that at least partially controls for 
misclassification of fertility related diagnosis and undiagnosed subfertility pathology.   
  Limitations of this study include the retrospective assessment of exposure that 
may result in both differential and nondifferential problems with recall. We sought to 
minimize problems with recall for treatment by the multimode, two stage FEQ. 
Additionally, there are some limitations in the accuracy of gestational age from birth 
certificates, which should be acknowledged, but these clinically relevant estimates are 
typically confirmed with early ultrasound. We did not distinguish between spontaneous 
labor and iatrogenic labor for women delivering at less than 37 weeks gestation: in future 
studies we recommend that this be taken into account.  
  Generalizability of findings may also be limited by the geographic location with a 
relatively homogenous racial and ethnic population. However, this homogenous 
population also allows for a more direct effect of the exposures to be evaluated as many 
of the unmeasured environmental, social, and genetic factors may be controlled for 
through sampling.  
  PTB is a significant public health issue worldwide. In the United States more than 
11% of live born infants are born at gestational ages <37 weeks. PTB contributes largely 
to infant and child morbidity and mortality.27, 28 More than 26.2 billion dollars are spent 
in the United States each year on costs associated with PTB.23 The findings from this 
analysis suggest that all medical fertility treatments, as practiced in this State, contribute 
directly to the incidence of PTB, principally by increasing multiple births. Efforts should 
be made to reduce the incidence of multiple gestations from all fertility treatments, not 
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just IVF.29, 30 However, based on these and other data, we cannot exclude the possibility 
that even if all multiple gestations are eliminated, there may remain some risk for preterm 
birth among singletons.12 Thus, we support the need for more rigorous population 
surveillance on the use of all fertility treatments, not just IVF.31  
  We suggest that women who are experiencing difficulty conceiving should 
consider first the opportunity for conception with less invasive treatments or no 
treatment. Although the time to conception may be longer, the potential for improved 
optimal birth outcomes should be weighed strongly against the desire to conceive faster. 
Additional research needs to be conducted to assess time to live birth in subfertile 
populations using a variety of fertility treatments.32 The risk of PTB after conception 
using OS or IUI is increased on an even greater magnitude to smoking, yet clinicians and 
patients may pay less attention to the risk of treatment.33, 34  
  In conclusion, our findings support efforts to encourage women to give an 
adequate trial of the least invasive fertility treatment that may work for them, to modify 
the practice of all fertility treatments to minimize incidence of multiple gestation and  to 
increase vigilance during prenatal care for pregnancies of all women with subfertility, 
regardless of treatment received.  Future research should consider interventions that may 
prevent preterm birth among these higher risk populations of subfertile women 





Figure 4.1 Flowchart of study participation, pregnancy outcome, and data linkage  























































Table 4.1 Characteristics of women by preterm birth (<37 weeks gestational age) 
 
  Term (>37 wks) Preterm (<37 wks) Total 
P-Value 
  N Row% N Row% N Col% 
Maternal Age at delivery               
≤30 290 81.7% 65 18.3% 355 72.4% 0.669 
31+ 108 80.0% 27 20.0% 135 27.6%   
Paternal age at delivery               
≤30 239 83.0% 49 17.0% 288 58.9% 0.223 
31+ 158 78.6% 43 21.4% 201 41.1%   
BMI Category  (pre-pregnancy)              
Underweight/Normal 184 76.0% 58 24.0% 242 55.1% 0.148 
Overweight/Obese 161 81.7% 36 18.3% 197 4.9%   
Income (at Interview)               
Less than $50,000 110 81.5% 25 18.5% 135 28.7% 0.938 
50,000-$99,999 213 80.1% 53 19.9% 266 56.6%   
Over $100,000 56 81.2% 13 18.8% 69 14.7%   
Education Level (at Interview)               
Less than college grad 127 77.4% 37 22.6% 164 33.6% 0.136 
College grad or more 269 83.0% 55 17.0% 324 66.4%   
Race/Ethnicity               
White, Non-Hispanic 381 80.9% 90 19.1% 471 96.1% 0.348 
Hispanic, Other Non-White 17 89.5% 2 10.5% 19 3.9%   
Religion               
Non-LDS 84 78.5% 23 21.5% 107 21.8% 0.415 
Latter-Day Saint 314 82.0% 69 18.0% 383 78.2%   
Insurance Coverage for Tx or DX               
None or unsure 40 88.9% 5 11.1% 45 9.2% 0.330 
Some insurance coverage  101 82.1% 22 17.9% 123 25.1%   
Not asked 257 79.8% 65 20.2% 322 65.7%   
Attempt duration to conception               
<12mo 69 81.2% 16 18.8% 85 17.4% 0.771 
12-<24 100 81.3% 23 18.7% 123 25.2%   
24-<36 73 85.9% 12 14.1% 85 17.4%   
36-<48 58 79.5% 15 20.5% 73 14.9%   
48+ 97 78.9% 26 21.1% 123 25.2%   
Recruitment Cohort               
Clinic 203 76.3% 63 23.7% 266 54.3% 0.002 
Population 195 87.1% 29 12.9% 224 45.7%   
Baby sex               
F 188 79.0% 50 21.0% 238 48.6% 0.219 
M 210 83.3% 42 16.7% 252 51.4%   
Multiplicity               
Singleton 374 90.8% 38 9.2% 412 84.1% 0.000 
Twins 24 33.8% 47 66.2% 71 14.5%   
Triplets 0 0.0% 7 100.0% 7 1.4%   
Successful Tx                
None 190 89.2% 23 10.8% 214 43.5% 0.001 
Drugs 61 79.2% 16 20.8% 77 15.7%   
IUI 48 75.0% 16 25.0% 64 13.1%   
IVF 99 72.8% 37 27.2% 136 27.8%   




Table 4.2 Treatment during the conception cycle by infertility etiology (N = 490) 
  None Drugs IUI IVF Total P-value 
  N Row% N Row% N Row% N Row% N Col%   
Tubal Factor 29 37.2% 14 17.9% 9 11.5% 26 33.3% 78 15.9% 0.550 
Endometriosis 49 37.4% 18 13.7% 19 14.5% 45 34.4% 131 26.7% 0.169 
Ovulation Dysfunction 99 37.5% 63 23.9% 41 15.5% 61 23.1% 264 53.9% 0.000 
Uterine Factor 20 30.8% 7 10.8% 12 18.5% 26 40.0% 65 13.3% 0.022 
Male Factor 60 30.8% 21 10.8% 27 13.8% 87 44.6% 195 39.8% 0.000 
Unexplained infertility 136 47.4% 43 15.0% 32 11.1% 76 26.5% 287 59.5% 0.176 
Multiple Female Factors 45 32.6% 26 18.8% 25 18.1% 42 30.4% 138 28.2% 0.014 
Multiple Female and Male  43 33.1% 19 14.6% 16 12.3% 52 40.0% 130 26.5% 0.002 





Table 4.3 Birth outcomes by reported infertility etiology (N = 490) 
  Term Preterm Total P-Value 
  N Row% N Row% N Col%   
Tubal Factor               
No 341 82.8% 71 17.2% 412 84.1% 0.044 
Yes 57 73.1% 21 26.9% 78 15.9%   
Endometriosis               
No 299 83.3% 60 16.7% 359 73.3% 0.053 
Yes 99 75.6% 32 24.4% 131 26.7%   
Ovulation Dysfunction               
No 190 84.1% 36 15.9% 226 46.1% 0.135 
Yes 208 78.8% 56 21.2% 264 53.9%   
Uterine Factor               
No 347 81.6% 78 18.4% 425 86.7% 0.540 
Yes 51 78.5% 14 21.5% 65 13.3%   
Male Factor               
No 243 82.4% 52 17.6% 295 60.2% 0.423 
Yes 155 79.5% 40 20.5% 195 39.8%   
Unexplained infertility               
Yes 156 80.0% 39 20.0% 195 40.5% 0.604 
No 235 81.9% 52 18.1% 287 59.5%   
Multiple Female Factors               
No 294 83.5% 58 16.5% 352 71.8% 0.037 
Yes 104 75.4% 34 24.6% 138 28.2%   
Multiple Female and Male Factors               
No 299 83.1% 61 16.9% 360 73.5% 0.084 
Yes 99 76.2% 31 23.8% 130 26.5%   
Total 398 81.2% 92 18.8% 490 100.0%   
 *chi2 comparing to women who were not told or suspect diagnosis 
• Diagnostics Categories--SART CORS classification  
o Tubal Factor—pelvic adhesion or scarring, blocked or damaged fallopian tubes 
o Endometriosis 
o Ovulation dysfunction-low progesterone, low estrogen, not ovulating, abnormal ovulation , lutenized unruptured 
follicule (LUF), Luteal Phase Defect (LUD), PCOS 
o Uterine Factor—hostile or limited cervical mucus, fibroids in the uterus, polyps in the uterus, 
o Male Factor  
o Unknown- Unexplained Subfertility  
o Multiple Female Factor- More than one of the following diagnosis Tubal, Endometriosis, Ovulation dysfunction, or 
Uterine 





Table 4.4 Fertility treatments used during the month of conception and most invasive 
fertility treatment used previously 
 
 
 Most invasive treatment during conception attempt but not during conception cycle  Intervention used during conception cycle 
 None Drugs IUI IVF Total None 51.6% 14.7% 16.1% 15.7% 213 Drugs 0.0% 83.6% 13.7% 8.2% 77 IUI 0.0% 0.0% 93.8% 6.3% 64 IVF 0.0% 0.0% 0.0% 100.0% 136  Total 113 92 105 180 490 
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Table 4.5 Multivariable logistic regression models for risk of preterm birth   
 
  Unadjusted OR [95% CI] Model 1: aOR [95% CI] Model 2: aOR [95% CI] Model 3: aOR     [95% CI] Model 4: aOR [95% CI]*  
Maternal age at Delivery           
≤30 Reference Reference Reference  Reference  Reference  
31+ 1.11 [0.68-1.83] 1.02 [0.51-2.04] 1.03 [0.5-2.09] 0.91 [0.38-2.19] 0.41 [0.13-1.28] 
Paternal age at Delivery           
≤30 Reference Reference Reference  Reference  Reference  
31+ 1.33 [0.84-2.09] 1.39 [0.74-2.62] 1.54 [0.8-2.97] 1.42 [0.64-3.13] 2.55 [0.98-6.65] 
BMI Category (at delivery)           
Underweight/Normal Reference Reference Reference  Reference  Reference  
Overweight/ Obese 0.94 [0.57-1.54] 0.93 [0.55-1.59] 0.9 [0.52-1.55] 1.19 [0.61-2.33] 1.72 [0.75-3.95] 
Income            
Less than $50,000 Reference Reference Reference  Reference  Reference  
50,000-$99,999 1.09 [0.65-1.86] 1.09 [0.58-2.04] 1.13 [0.6-2.14] 0.81 [0.38-1.72] 1.28 [0.5-3.24] 
Over $100,000 1.02 [0.49-2.15] 0.73 [0.29-1.86] 0.71 [0.28-1.84] 0.85 [0.27-2.73] 1.16 [0.28-4.87] 
Education Level           
Less than college grad Reference Reference Reference  Reference  Reference  
College grad or more 0.70 [0.44-1.12] 0.67 [0.39-1.16] 0.7 [0.4-1.23] 0.84 [0.42-1.67] 0.45 [0.2-1.05] 
Religion           
Non-LDS Reference Reference Reference  Reference  Reference  
Latter-Day Saint 0.80 [0.47-1.36] 0.85 [0.45-1.62] 0.87 [0.45-1.67] 0.73 [0.32-1.66] 0.85 [0.31-2.28] 
Most Invasive Tx used during cycle of 
conception            
None Reference Reference Reference  Reference  Reference  
Drugs 2.17 [1.08-4.36] 2.68 [1.25-5.76] 2.17 [0.99-4.75] 1.34 [0.52-3.45] 1.08 [0.34-3.4] 
IUI 2.75 [1.35-5.61] 3.5 [1.57-7.83] 3.17 [1.4-7.19] 2.16 [0.82-5.69] 1.98 [0.65-6.04] 
IVF 3.09 [1.74-5.48] 3.6 [1.86-7] 4.24 [2.05-8.77] 1.46 [0.59-3.58] 1.45 [0.48-4.37] 
Attempt duration ending in conception           
<24 Reference   Reference  Reference  Reference  
≥24 1.01 {0.64-1.59]   0.59 [0.33-1.06] 0.66 [0.33-1.34] 0.69 [0.3-1.6] 
Etiology            
No Female Factor     Reference Reference Reference 
Any Female Factor     2.99 [1.5-5.97] 3.00 [1.32-6.79] 4.9 [1.4-17.1] 
No Male Factor     Reference Reference Reference 
Any Male Factor      1.01 [0.58-1.76] 0.99 [0.51-1.95] 1.34 [0.57-3.13] 
Multiple Gestation            
Singleton Reference     Reference    
Multiple 22.14 [12.3-39.79]     27.91 [13.25-58.79]   
Model 1:maternal age, paternal age, prepregnancy BMI, Income, education, Religion, Infertility treatment used during month of conception 
Model 2: maternal age, paternal age, prepregnancy BMI, Income, education, Religion, Infertility treatment used during month of conception 
Model 3: maternal age, paternal age, prepregnancy BMI, Income, education, Religion, Infertility treatment used during month of conception, duration of infertility, female factor (ovulatory 
dysfunction, endometriosis, tubal factor, uterine factor), male factor fertility etiology, multiples 
Model 4: maternal age, paternal age, prepregnancy BMI, Income, education, Religion, Infertility treatment used during month of conception, duration of infertility,  female factor (ovulatory 
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5.1 Summary of Key Findings 
 
Aim 1 compared longest pregnancy attempt recall based on three different 
questioning approaches among women with a history of subfertility. The first approach 
uses a standard single question (single question approach); the second approach is a 
series of questions assessing discrete pregnancy attempts using specific dates for start and 
stop time at risk (date approach), and the third approach asks the woman for a date when 
she began “actively” trying to become pregnant (active date approach). We found that 
misestimation of longest single attempt duration occurred frequently when information 
was solicited using the common single question approach. Only a third (34%) of women 
accurately reported their longest attempt duration based on this single question when 
compared to information obtained using the date-based approach (+/- 3 months), while 
37% of women overestimated and 29% of women underestimated their TARP using the 
single question approach. Women who overestimated their longest attempt with the 
single question approach were older when their first attempt started, had higher BMIs, 
and had longer time intervals between their first attempt and the time of the interview 
than women who accurately estimated their TARP. Women who underestimated their 




had a longer time interval between the start of their first attempt and the date of the 
interview than those who accurately estimated. The risk of misestimation was 
significantly lower for women who had experienced a pregnancy (with or without live 
birth). 
Aim 2 describes use of behavioral, nonmedical, and medical interventions 
reported by women who experienced primary infertility. Women commonly use a mix of 
medical and nonmedical interventions while trying to conceive. Nearly all participants 
(94%) engaged in fertility-focused intercourse methods during at least one pregnancy 
attempt. A third of women (35%) either lost weight or changed their diet with the 
intention of enhancing their fertility. A third of women (n = 287) also reported using 
CAM in at least one attempt but only 4% (n = 31) reported CAM as their most invasive 
treatment. There was a high rate of medical treatment used in this population, with 81% 
(n = 703) reporting some type of medical treatment, including OS, IUI, and/or ART.  
Rates of partner-focused interventions were low in both cohorts. The most common 
intervention used by male partners was weight loss (6%). Women reported that male 
partners also used fertility diets (5%), vitamins (6%), herbs (5%), acupuncture (2%), 
medications such as Clomid (3%), and hormonal treatments (3%). Overall, only 15% (n = 
133) of women in this cohort never used any intervention to enhance their fertility.  
Compared to women recruited from specialty infertility clinics, women from the general 
population were less likely to use any type of medical treatment, but equally likely to use 
nonmedical interventions. During the pregnancy attempt history, women frequently 
reported using more than one method to enhance their fertility. The average number of 
interventions used was 3.4, but ranged from 0 to 8 (potential maximum is 9). Women 
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recruited from the specialty clinics used different types of treatments than women 
recruited from the general population; however, there was no difference in the proportion 
of women achieving at least one pregnancy in the two groups (64% versus 63%; p = 
0.76). There were significantly more clinic-recruited women who had at least one 
pregnancy ending in a multiple gestation birth compared to women recruited from the 
population (23% versus 11%; p-value < 0.01).  
Aim 3 examined the effect of fertility treatment OS, IUI, and IVF on PTB 
compared to no treatment in subfertile women.  Among linked births, 19% were born 
prior to 37 weeks completed gestation. After adjustment for maternal age, paternal age, 
maternal education, annual income, religious affiliation, female or male fertility 
diagnosis, and duration of subfertility, the odds of having a PTB were 2.2 times higher 
(95% CI 1.0-4.8) for women who conceived using ovulation drugs, 3.2 times higher 
(95% CI 1.4-7.2) for women who conceived using IUI and 4.2 times higher (95% CI 2.1-
8.8) for women who conceived by IVF, compared to women with subfertility who used 
no treatment during the month of conception. Duration of pregnancy attempt was not 
independently associated with PTB. A reported diagnosis of female factor infertility 
increased the adjusted odds of having a PTB was 3.0 times higher (95% CI 1.5-6.0) 
compared to women who did not report any female factor infertility.  Although slightly 
attenuated when excluding women with tubal factor, the odds of PTB were still 
significant (aOR 2.75; 95% CI 1.42-5.31) for women with any female factor infertility. 
Only 6.6% of the births conceived without any treatment during the month of conception 
were twins, and for OS this increased to 19% twins and 6% triplets, IUI births were 
10.9% twins and 5% triplets, and IVF births were 30% twins and 2% triplets.  Multiple 
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gestations had the highest association with adverse neonatal outcomes (aOR 28.0; 95% 
CI 15.6-68.6) when controlling for all other variables. In restricting analyses to singleton 
gestation, odds ratios remained elevated but were no longer significant for any type of 
treatment. However, female factor infertility was found to be independently associated 
with PTB when controlling for treatment, multiple gestations, and other potential 
confounders.   
 
5.2 Clinical Implications and Recommendations 
 
The findings from Aim 1 highlight the value of taking a detailed attempt history 
using a date-based approach. The fact that women who experienced a pregnancy 
(regardless of live birth) were better at recalling attempt duration supports the use of a 
life event history framework.14 The findings of this research also caution against 
assuming that biological TARP is equivalent to what is commonly referred to as “trying 
to conceive,” which is imbued with intentionality, or that either of these measures can be 
determined using a single question. In 2013, The Practice Committee of the American 
Society for Reproductive Medicine updated the definition of subfertility to include the 
phrase “12 months or more of appropriately timed unprotected intercourse or 
therapeutic donor insemination.” This should be incorporated into questions assessing 
pregnancy attempt duration. Variations can cause bias in self-reports of time trying to 
conceive, skew fertility prognosis, and alter treatment plans. Physicians, in primary care 
and specialty settings, should avoid the use of a single question when assessing how long 
a couple has been having regular unprotected intercourse. Detailed attempt histories 
should be used to capture a more accurate and complete picture of “time trying to 
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conceive,” including reports of the number of cycles using “fertility focused intercourse.”   
Providers should also understand the potential impact of inaccurate pregnancy attempt 
reporting on patient treatment recommendations, which can unnecessarily increase 
patient’s risk for undergoing potentially unnecessary treatments, which increase costs and 
may put them at risk for adverse perinatal outcomes. 
Aim 2 demonstrated the necessity for providers to complete a full intervention 
inventory in addition to medical history with patients at all clinical encounters. Having a 
more complete picture of the things that women are doing either on their own or with 
CAM practitioners or other medical providers can improve treatment precision. Providers 
need to acknowledge that more likely than not their patients are engaging in nonmedical 
interventions with the intention of enhancing their fertility, but without adequate 
counseling women may be using approaches that could have opposing effects on 
treatments. Women who have been trying for longer are also more likely to engage in 
more interventions and should be asked to report on the things they may have tried over 
the years. The use of an intervention checklist to assess what nonmedical interventions 
patients are using has the potential to create open communication between patients and 
specialty providers by removing stigma surrounding nonmedical CAM and ensuring that 
providers have the most complete clinical picture when treating individual cases. This 
may also be an opportunity to ensure that their long durations of “regular, unprotected 
intercourse” also included at least 12 cycles of appropriate fertility-focus intercourse. 
These interactions with patients who are struggling to conceive is an ideal opportunity to 




Findings from aim 3 suggest that women who are experiencing difficulty 
conceiving should consider first the opportunity for conception with less invasive 
treatments or no treatment. Providers should support this through disclosure of known 
risk and benefits for all treatment types. Although the time to conception may be longer, 
the potential for improved optimal birth outcomes should be weighed strongly against the 
desire to conceive faster. Clinicians should modify the practice of all fertility treatments 
to minimize incidence of multiple gestation, using OS methods with lower risk of 
superovulation, and single embryo transfer when providing IVF. Additionally, increased 
vigilance should be practiced during prenatal care for all women with subfertility, 
regardless of treatment received.  
 
5.3 Future Directions 
 
Each of the aims successfully answered the objectives at hand yet there is still 
need for additional research to solidify these findings. There is a need to conduct 
prospective research assessing biological time at risk for pregnancy, pregnancy attempt 
duration where a couples is explicitly intending to conceive, and behavioral “active” 
attempt or cycles of fertility focused intercourse. The potential for recall error is 
substantial in retrospective research and has to be acknowledged as a limitation of the 
research presented here. A prospective study would allow for a true gold standard of 
biological time at risk among a preconception cohort. 
 Research should also be conducted to evaluate cumulative pregnancy rates and 
neonatal outcomes when fertility treatment is delayed until couples meet the 12 cycles of 
appropriately timed intercourse rather than using the more subjective measures of 12 
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months of regular unprotected intercourse.  
Aim 2 provided a glimpse into what nonmedical and behavioral interventions are 
being used in a population that may or may not have seen any specialty providers for 
difficulty conceiving. The study was limited by small numbers of women using some of 
the interventions, including partner-focused interventions. A larger prospective trial 
should be conducted to assess if nonmedical CAM, or behavioral interventions for both 
male and female partners, have any meaningful effect on conception in populations of 
subfertile couples.  
Aim 3 found a direct effect of all types fertility treatment on the risk of preterm 
birth. Research on the non-ART approaches would be more feasible if universally there 
were improved surveillance of all fertility treatments (including less invasive OS and 
IUI). The findings were consistent with previously published research in identifying an 
increased risk on preterm birth, and future research should consider potential 
preconception or prenatal interventions that may prevent preterm birth among these 
higher risk populations of subfertile women conceiving using any fertility treatments.  
 
